NZ749820B2 - Anti-tim-3 antibodies - Google Patents
Anti-tim-3 antibodies Download PDFInfo
- Publication number
- NZ749820B2 NZ749820B2 NZ749820A NZ74982017A NZ749820B2 NZ 749820 B2 NZ749820 B2 NZ 749820B2 NZ 749820 A NZ749820 A NZ 749820A NZ 74982017 A NZ74982017 A NZ 74982017A NZ 749820 B2 NZ749820 B2 NZ 749820B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- amino acid
- antibody
- acid sequence
- cancer
- Prior art date
Links
- 102000004965 antibodies Human genes 0.000 title claims abstract description 803
- 108090001123 antibodies Proteins 0.000 title claims abstract description 803
- 102100016384 HAVCR2 Human genes 0.000 claims abstract description 597
- 101710004393 HAVCR2 Proteins 0.000 claims abstract description 595
- 101700008936 Tim8 Proteins 0.000 claims abstract description 594
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 408
- 201000011510 cancer Diseases 0.000 claims description 244
- 239000003814 drug Substances 0.000 claims description 87
- 238000004519 manufacturing process Methods 0.000 claims description 79
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 31
- 201000005202 lung cancer Diseases 0.000 claims description 31
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 27
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- 206010017758 Gastric cancer Diseases 0.000 claims description 24
- 206010025650 Malignant melanoma Diseases 0.000 claims description 24
- 201000001441 melanoma Diseases 0.000 claims description 24
- 206010006187 Breast cancer Diseases 0.000 claims description 23
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 23
- 206010033128 Ovarian cancer Diseases 0.000 claims description 23
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 23
- 206010060862 Prostate cancer Diseases 0.000 claims description 23
- 206010038389 Renal cancer Diseases 0.000 claims description 23
- 206010039491 Sarcoma Diseases 0.000 claims description 23
- 201000011231 colorectal cancer Diseases 0.000 claims description 23
- 201000004101 esophageal cancer Diseases 0.000 claims description 23
- 201000010536 head and neck cancer Diseases 0.000 claims description 23
- 201000010982 kidney cancer Diseases 0.000 claims description 23
- 201000007270 liver cancer Diseases 0.000 claims description 23
- 201000002528 pancreatic cancer Diseases 0.000 claims description 23
- 201000011549 stomach cancer Diseases 0.000 claims description 23
- 210000004962 mammalian cells Anatomy 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 29
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- 201000005787 hematologic cancer Diseases 0.000 abstract description 2
- 230000027455 binding Effects 0.000 description 114
- 210000004027 cells Anatomy 0.000 description 75
- 102100011828 CEACAM1 Human genes 0.000 description 51
- 101710043957 CEACAM1 Proteins 0.000 description 51
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 45
- 101000245034 LGALS9 Proteins 0.000 description 42
- 102000030214 human LGALS9 protein Human genes 0.000 description 42
- 238000002424 x-ray crystallography Methods 0.000 description 33
- 125000000539 amino acid group Chemical group 0.000 description 30
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 24
- 201000005112 urinary bladder cancer Diseases 0.000 description 23
- 206010005003 Bladder cancer Diseases 0.000 description 22
- 108010045030 monoclonal antibodies Proteins 0.000 description 21
- 102000005614 monoclonal antibodies Human genes 0.000 description 21
- 238000004166 bioassay Methods 0.000 description 18
- 210000004408 Hybridomas Anatomy 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 230000003993 interaction Effects 0.000 description 15
- 230000000903 blocking Effects 0.000 description 14
- 210000001744 T-Lymphocytes Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 102000038129 antigens Human genes 0.000 description 11
- 108091007172 antigens Proteins 0.000 description 11
- 239000002609 media Substances 0.000 description 11
- 229920000023 polynucleotide Polymers 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 7
- 230000035693 Fab Effects 0.000 description 7
- 230000016396 cytokine production Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 210000001616 Monocytes Anatomy 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 101710015837 LGALS9 Proteins 0.000 description 4
- 102100004651 LGALS9 Human genes 0.000 description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 description 4
- 239000007759 RPMI Media 1640 Substances 0.000 description 4
- 210000002845 Virion Anatomy 0.000 description 4
- 230000000259 anti-tumor Effects 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000001413 cellular Effects 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108091000081 Phosphotransferases Proteins 0.000 description 3
- 102000030951 Phosphotransferases Human genes 0.000 description 3
- 230000035492 administration Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000007374 clinical diagnostic method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 238000003260 fluorescence intensity Methods 0.000 description 3
- 230000002519 immonomodulatory Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- -1 peptide Proteins 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010059512 Apoptosis Diseases 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 2
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 2
- 102100003268 CD14 Human genes 0.000 description 2
- 101700027514 CD14 Proteins 0.000 description 2
- 210000004443 Dendritic Cells Anatomy 0.000 description 2
- 102100009498 HMGB1 Human genes 0.000 description 2
- 101700084087 HMGB1 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100016020 IFNG Human genes 0.000 description 2
- 101700086956 IFNG Proteins 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 229910004682 ON-OFF Inorganic materials 0.000 description 2
- 210000004681 Ovum Anatomy 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000003899 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000003370 grooming Effects 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-Tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N Bis-tris methane Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 102100015324 CADM1 Human genes 0.000 description 1
- 101700026482 CCRL2 Proteins 0.000 description 1
- 102100019461 CD28 Human genes 0.000 description 1
- 101700033362 CD28 Proteins 0.000 description 1
- 102100011842 CEACAM5 Human genes 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 102100015545 FCGR2A Human genes 0.000 description 1
- 102100015541 FCGR3A Human genes 0.000 description 1
- 101710044656 FCGR3A Proteins 0.000 description 1
- 101710044657 FCGR3B Proteins 0.000 description 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N FOLFIRI regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 101700009480 Fcgr3 Proteins 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101710007377 H1-4 Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 102100008982 IL17A Human genes 0.000 description 1
- 101710003110 IL17A Proteins 0.000 description 1
- 102100015975 IL17F Human genes 0.000 description 1
- 101700007032 IL17F Proteins 0.000 description 1
- 102100014199 IL25 Human genes 0.000 description 1
- 101700051492 IL25 Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100011008 LETMD1 Human genes 0.000 description 1
- 101710037953 LETMD1 Proteins 0.000 description 1
- 102100011831 LTA Human genes 0.000 description 1
- 101710040538 LTA Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108010019759 OVA 323-339 Proteins 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000000735 allogeneic Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 201000003963 colon carcinoma Diseases 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ANUSOIHIIPAHJV-UHFFFAOYSA-N fenticlor Chemical compound OC1=CC=C(Cl)C=C1SC1=CC(Cl)=CC=C1O ANUSOIHIIPAHJV-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 230000002601 intratumoral Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000007799 mixed lymphocyte reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005161 thyroid carcinoma Diseases 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
The present disclosure relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
Description
ANTI-TIM-3 ANTIBODIES
The present invention is in the field of medicine. Particularly, the present
invention generally relates to antibodies directed to T-cell immunoglobulin- and mucin-
domain-containing protein-3 (Tim-3), compositions comprising such anti-Tim-3
antibodies. Also described are methods of using such anti-Tim-3 antibodies for the
treatment of solid and hematological tumors alone or in combination with chemotherapy
and other cancer therapeutics.
Tumor cells escape detection and elimination by the immune system through a
variety of mechanisms. One such mechanism is by the manipulation of immune
checkpoint regulatory pathways that are normally used in the maintenance of self-
tolerance and control of T cell activation. Cancer cells can commandeer these immune
checkpoint regulatory pathways to suppress the anti-tumor response and prevent their
destruction.
Although T cells recognizing tumor antigens can be isolated from patients and
mouse models, such cells can exhibit an exhausted phenotype characterized by an
impairment in cytotoxic functions, effector cytokine production, and proliferation.
Moreover, such tumor-infiltrating T cells can express high levels of the checkpoint
regulator Tim-3. In this regard, it has been shown that anti-Tim-3 antibodies can restore
anti-tumor immunity in some murine cancer models.
Antibodies directed to human Tim-3 are known. Humanized antibodies against
human Tim-3 are described in WO15117002. MBG453, an anti-human Tim-3 antibody,
is also currently being tested in human clinical trials. However, no antibody targeting
Tim-3 has been approved for therapeutic use in humans.
Tim-3 has been shown to interact with galectin-9 (SEQ ID NO:40),
phosphaditylserine (C H NO P), high-mobility group Box 1 (HMGB1), and
13 24 10
carcinoembryonic antigen cell adhesion molecule 1(CEACAM1) (SEQ ID NO:39).
CEACAM1 expression in the primary tumors of melanoma patients has been shown to be
associated with the subsequent development of metastatic disease (Thies et al., J. Clin.
Oncol. 20, (2002), pp. 2530-2536). Additionally, CEACAM1 expression has been shown
to be a prognosticator for unfavorable non-small cell lung cancer (NSCLC) related
survival, an independent risk factor for lymph node metastasis of colon carcinomas,
associated with urinary bladder cancer and muscle invasiveness, present on thyroid
carcinoma cell lines derived from tumors showing aggressive behavior, and associated
with a more malignant transformation in gastric carcinomas (Fiori et al., Ann. Ist. Super
Sanita 48 (2012), pp. 161-171). With regards to galectin-9, tumor-derived galectin-9 has
been shown to induce the apoptosis of tumor-infiltrating Tim-3 CD8 T cells in a CT26
mouse colon tumor model (Kang, C.W. et al., Sci. Rep. 5:15659 (2015).
Because all of the aforementioned Tim-3 ligands are not exclusive ligands of Tim-
3, it is desirable to provide therapeutic anti-Tim-3 antibodies that differentially block the
activity of said ligands as these ligands can regulate the immune system independently of
Tim-3. Such a strategy can provide alternative ways to more specifically modulate Tim-3
activity, allowing for tailored immuno-oncology based therapies for patients.
Furthermore, such anti-Tim-3 antibodies can provide options for combinatorial therapies
with other checkpoint inhibitors, providing alternatives that may display improved
efficacy and toxicity profiles when combined with other therapeutics. Thus, there
remains a need to provide antibodies that bind human Tim-3 and inhibit Tim-3’s
interactions with some of Tim-3’s ligands, but not others.
There also remain a need for alternative anti-human Tim-3 antibodies that may be
clinically beneficial. In particular, there remains a need for alternative anti-Tim-3
antibodies that specifically bind human Tim-3 and alleviate immune exhaustion such as
the failure of the T cell to produce cytokines. There also remains a need for alternative
anti-Tim-3 antibodies that specifically bind human Tim-3 and enhance the anti-tumor
immune response. There also remains a need for anti-human Tim-3 antibodies that
display sufficient potency as a cancer monotherapy. It is an object of the present
invention to address these needs, and/or to at least provide the public with a useful choice.
Certain statements that appear below are broader than what appears in the claims.
These statements are provided in the interests of providing the reader with a better
understanding of the invention and its practice. The reader is directed to the
accompanying claim set which defines the scope of the invention.
Anti-Tim-3 antibodies of the present invention can block human Tim-3’s binding
with human galectin-9 and phosphatidylserine while simultaneously not blocking the
binding of human Tim-3 and human CEACAM1. Surprisingly, the anti-Tim-3 antibodies
of the present invention enhance T cell responses to tumors as measured by tumor size in
established tumor models by blocking the interaction of human Tim-3 with human
phosphatidylserine and human galectin-9 while not blocking the interaction of human
CEACAM1 with human Tim-3. Surprisingly, certain anti-Tim-3 antibodies of the present
invention mediate enhanced T cell responses to a tumor as measured by CD8-positive
CD3-positive T cell infiltration or persistence by blocking the interaction of human Tim-3
with human phosphatidylserine and human galectin-9 while not blocking the interaction
of human CEACAM1 with human Tim-3.
Described is an antibody that binds human Tim-3 (SEQ ID NO: 1), the antibody
comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the
amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17,
18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively.
In one aspect, the present invention provides an antibody that binds human Tim-3,
(SEQ ID NO:1), the antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2,
and LCDR3 wherein:
a) HCDR1 has the amino acid sequence of SEQ ID: 2, HCDR2 has the amino
acid sequence of SEQ ID NO: 3, HCDR3 has the amino acid sequence of SEQ
ID NO: 4, LCDR1 has the amino acid sequence of SEQ ID NO:5, LCDR2 has
the amino acid sequence of SEQ ID NO:6, and LCDR3 has the amino acid
sequence of SEQ ID NO:7;
b) HCDR1 has the amino acid sequence of SEQ ID NO:14, HCDR2 has the
amino acid sequence of SEQ ID NO:15, HCDR3 has the amino acid sequence
of SEQ ID NO:16, LCDR1 has the amino acid sequence of SEQ ID NO:17,
LCDR2 has the amino acid sequence of SEQ ID NO:18, and LCDR3 has the
amino acid sequence of SEQ ID NO:19; or
c) HCDR1 has the amino acid sequence of SEQ ID NO:26, HCDR2 has the
amino acid sequence of SEQ ID NO:27, HCDR3 has the amino acid sequence
of SEQ ID NO:28, LCDR1 has the amino acid sequence of SEQ ID NO:29,
LCDR2 has the amino acid sequence of SEQ ID NO:30, and LCDR3 has the
amino acid sequence of SEQ ID NO:31.
The present invention provides an antibody that binds human Tim-3 (SEQ ID
NO: 1), the antibody comprising a HCDR1 of SEQ ID NO:2, HCDR2 of SEQ ID NO:3,
HCDR3 of SEQ ID NO:4, LCDR1 of SEQ ID NO:5, LCDR2 of SEQ ID NO:6, and
LCDR3 of SEQ ID NO:7.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a HCDR1 of SEQ ID NO:14, HCDR2 of SEQ ID NO:15,
HCDR3 of SEQ ID NO:16, LCDR1 of SEQ ID NO:17, LCDR2 of SEQ ID NO:18, and
LCDR3 of SEQ ID NO:19.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a HCDR1 of SEQ ID NO:26, HCDR2 of SEQ ID NO:27,
HCDR3 of SEQ ID NO:28, LCDR1 of SEQ ID NO:29, LCDR2 of SEQ ID NO:30, and
LCDR3 of SEQ ID NO:31.
In another aspect, the invention provides an antibody, comprising a heavy chain
variable region (HCVR) and a light chain variable region (LCVR), wherein:
a) the HCVR has the amino acid sequence of SEQ ID NO: 8, and the LCVR
has the amino acid sequence of SEQ ID NO: 9;
b) the HCVR has the amino acid sequence of SEQ ID NO: 20, and the LCVR
has the amino acid sequence of SEQ ID NO: 21; or
c) the HCVR has the amino acid sequence of SEQ ID NO: 32, and the LCVR
has the amino acid sequence of SEQ ID NO: 33.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a heavy chain variable region (HCVR) and a light chain
variable region (LCVR), wherein: the HCVR has the amino acid sequence given in SEQ
ID NO: 8, and the LCVR has the amino acid sequence given in SEQ ID NO: 9; the
HCVR has the amino acid sequence given in SEQ ID NO: 20, and the LCVR has the
amino acid sequence given in SEQ ID NO: 21; or the HCVR has the amino acid sequence
given in SEQ ID NO: 32, and the LCVR has the amino acid sequence given in SEQ ID
NO: 33.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a heavy chain variable region (HCVR) and a light chain
variable region (LCVR), wherein: the HCVR has the amino acid sequence given in SEQ
ID NO: 8, and the LCVR has the amino acid sequence given in SEQ ID NO: 9.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a heavy chain variable region (HCVR) and a light chain
variable region (LCVR), wherein: the HCVR has the amino acid sequence given in SEQ
ID NO: 20, and the LCVR has the amino acid sequence given in SEQ ID NO: 21.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a heavy chain variable region (HCVR) and a light chain
variable region (LCVR), wherein: the HCVR has the amino acid sequence given in SEQ
ID NO: 32, and the LCVR has the amino acid sequence given in SEQ ID NO: 33.
In another aspect, the invention provides an antibody, comprising a heavy chain
(HC) and a light chain (LC), wherein:
a. the HC has the amino acid sequence of SEQ ID NO: 10 and the LC has the
amino acid sequence of SEQ ID NO: 11;
b. the HC has the amino acid sequence of SEQ ID NO: 22 and the LC has the
amino acid sequence of SEQ ID NO: 23; or
c. the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the
amino acid sequence of SEQ ID NO: 35.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a heavy chain (HC) and a light chain (LC), wherein the HC
and the LC have the amino acid sequences given in SEQ ID NOs: 10 and 11,
respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a heavy chain (HC) having the amino acid sequence of SEQ
ID NO: 10,and a light chain (LC) having the amino acid of SEQ ID NO: 11.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a heavy chain (HC) having the amino acid sequence of SEQ
ID NO: 22 and a light chain (LC) having the amino acid sequence of SEQ ID NO: 23.
The present invention provides an antibody that binds human Tim-3 (SEQ ID NO:
1), the antibody comprising a heavy chain (HC) having the amino acid sequence of SEQ
ID NO: 34 and a light chain (LC) having the amino acid sequence of SEQ ID NO: 35.
The present invention provides an anti-human Tim-3 antibody, comprising two
heavy chains and two light chains, wherein each heavy chain (HC) has the amino acid
sequence of SEQ ID NO: 10 and each light chain (LC) has the amino acid sequence of
SEQ ID NO: 11.
The present invention provides an anti-human Tim-3 antibody, comprising two
heavy chains and two light chains, wherein each heavy chain (HC) has the amino acid
sequence of SEQ ID NO:22 and each light chain (LC) has the amino acid sequence of
SEQ ID NO:23.
The present invention provides an anti-human Tim-3 antibody, comprising two
heavy chains and two light chains, wherein each heavy chain (HC) has the amino acid
sequence of SEQ ID NO: 34 and each light chain (LC) has the amino acid sequence of
SEQ ID NO: 35.
Also described is an antibody that binds the same epitope on human Tim-3 (SEQ
ID NO: 1), as an antibody comprising a HCDR1 of SEQ ID NO:2, HCDR2 of SEQ ID
NO:3, HCDR3 of SEQ ID NO:4, LCDR1 of SEQ ID NO:5, LCDR2 of SEQ ID NO:6,
and LCDR3 of SEQ ID NO:7. Also described is an antibody that binds the same epitope
on human Tim-3 (SEQ ID NO: 1), as antibody comprising a heavy chain variable region
(HCVR) and a light chain variable region (LCVR), wherein: the HCVR has the amino
acid sequence given in SEQ ID NO: 8, and the LCVR has the amino acid sequence given
in SEQ ID NO: 9. Also described is an antibody that binds the same epitope on human
Tim-3 (SEQ ID NO: 1), as an antibody comprising a heavy chain (HC) having the amino
acid sequence of SEQ ID NO: 10, and a light chain (LC) having the amino acid of SEQ
ID NO: 11.
Also described is a monoclonal antibody that binds human Tim-3 (SEQ ID NO:1),
wherein said antibody blocks binding of human Tim-3 to human phosphatidylserine, but
does not block binding of human Tim-3 to human CEACAM1 (SEQ ID: 39). Also
described is a monoclonal antibody that binds human Tim-3 (SEQ ID NO:1), wherein
said antibody blocks binding of human Tim-3 to human phosphatidylserine and human
galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3 to human
CEACAM1 (SEQ ID: 39).
Also described is an antibody that binds a human Tim-3 (SEQ ID NO:1) epitope,
wherein the antibody contacts residues 50, 55-65, 72, 107, 111, 113-120, and 122 of
human Tim-3 (SEQ ID NO:1). Also described is an antibody that binds an epitope on
human Tim-3 (SEQ ID NO:1), wherein the antibody contacts residues 50, 55-65, 72, 107,
111, 113-120, and 122 of human Tim-3 (SEQ ID NO:1); wherein the epitope is
determined by X-ray crystallography and wherein the residues in contact are within six
(6) angstroms or less of the antibody. Also described is an antibody that binds a human
Tim-3 (SEQ ID NO:1) epitope, wherein the antibody contacts residues 50, 55-65, 72, 107,
111, 113-120, and 122 of human Tim-3 (SEQ ID NO:1); wherein the epitope is
determined by X-ray crystallography and wherein the residues in contact are within six
(6) angstroms or less of the antibody; wherein said antibody blocks binding of human
Human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID
NO:1) to human galectin-9 (SEQ ID: 40) (SEQ ID: 40), but does not block binding of
human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1),
wherein the antibody contacts at least one residue of the following: 50, 55, 62-65
(inclusive), 72, 111, and 113-118 (inclusive). Also described is an antibody that binds an
epitope on human Tim-3 (SEQ ID NO:1), wherein the antibody contacts at least one
residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive);
wherein the epitope is determined by X-ray crystallography and wherein the residues in
contact are within six (6) angstroms or less of the antibody. Also described is an antibody
that binds an epitope on human Tim-3 (SEQ ID NO:1), wherein the antibody contacts at
least one residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118
(inclusive); wherein the epitope is determined by X-ray crystallography and wherein the
residues in contact are within six (6) angstroms or less of the antibody; wherein said
antibody blocks binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine
and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ ID: 40), but does not block
binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1),
wherein the antibody contacts at least one residue of the following: 50, 55, 62-65
(inclusive), 72, 111, and 113-118 (inclusive), wherein the antibody contacts: at least two
of the residues; preferably at least three of the residues; more preferably at least four of
the residues; more preferably at least five of the residues; more preferably at least six of
the residues; more preferably at least seven of the residues; more preferably at least eight
of the residues; more preferably at least nine of the residues; more preferably at least ten
of the residues; more preferably at least eleven of the residues; more preferably at least
twelve of the residues; more preferably at least thirteen of the residues; or more
preferably all of the residues.
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1),
wherein the antibody contacts at least one residue of the following: 50, 55, 62-65
(inclusive), 72, 111, and 113-118 (inclusive), wherein the antibody contacts: at least two
of the residues; preferably at least three of the residues; more preferably at least four of
the residues; more preferably at least five of the residues; more preferably at least six of
the residues; more preferably at least seven of the residues; more preferably at least eight
of the residues; more preferably at least nine of the residues; more preferably at least ten
of the residues; more preferably at least eleven of the residues; more preferably at least
twelve of the residues; more preferably at least thirteen of the residues; or more
preferably all of the residues; wherein the epitope is determined by X-ray crystallography
and wherein the residues in contact are within six (6) angstroms or less of the antibody;
wherein said antibody blocks binding of human Tim-3 (SEQ ID NO:1) to human
phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ ID: 40),
but does not block binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ
ID: 39).
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1),
wherein the antibody contacts at least one residue of the following: 50, 55, 62-65
(inclusive), 72, 111, and 113-118 (inclusive); and wherein the antibody further contacts at
least one residue of the following: 56-61 (inclusive), 107, 119-120 (inclusive) , and 122.
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1),
wherein the antibody contacts at least one residue of the following: 50, 55, 62-65
(inclusive), 72, 111, and 113-118 (inclusive); and wherein the antibody further contacts at
least one residue of the following: 56-61 (inclusive), 107, 119-120 (inclusive), and 122;
wherein the epitope is determined by X-ray crystallography and wherein the residues in
contact are within six (6) angstroms or less of the antibody; wherein said antibody blocks
binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3
(SEQ ID NO:1) to human galectin-9 (SEQ ID: 40), but does not block binding of human
Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1),
wherein the antibody contacts at least one residue of the following: 50, 55, 62-65
(inclusive), 72, 111, and 113-118 (inclusive), wherein the antibody contacts: at least two
of the residues; preferably at least three of the residues; more preferably at least four of
the residues; more preferably at least five of the residues; more preferably at least six of
the residues; more preferably at least seven of the residues; more preferably at least eight
of the residues; more preferably at least nine of the residues; more preferably at least ten
of the residues; more preferably at least eleven of the residues; more preferably at least
twelve of the residues; more preferably at least thirteen of the residues; or more
preferably all of the residues; and wherein the antibody further contacts at least one
residue of the following: 56-61 (inclusive), 107, 119-120 (inclusive), and 122.
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1),
wherein the antibody contacts at least one residue of the following: 50, 55, 62-65
(inclusive), 72, 111, and 113-118 (inclusive), wherein the antibody contacts: at least two
of the residues; preferably at least three of the residues; more preferably at least four of
the residues; more preferably at least five of the residues; more preferably at least six of
the residues; more preferably at least seven of the residues; more preferably at least eight
of the residues; more preferably at least nine of the residues; more preferably at least ten
of the residues; more preferably at least eleven of the residues; more preferably at least
twelve of the residues; more preferably at least thirteen of the residues; or more
preferably all of the residues; wherein the antibody further contacts at least one residue of
the following: 56-61 (inclusive), 107, 119-120 (inclusive), and 122; wherein the epitope
is determined by X-ray crystallography and wherein the residues in contact are within six
(6) angstroms or less of the antibody; and wherein said antibody blocks binding of human
Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to
human galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3 (SEQ ID
NO:1) to human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts
at least one amino acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and
113-118 (inclusive). An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the
antibody contacts at least one amino acid residue of the following: 50, 55, 62-65
(inclusive), 72, 111, and 113-118 (inclusive); optionally, wherein said antibody blocks
binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3
(SEQ ID NO:1) to human galectin-9 (SEQ ID: 40), but does not block binding of human
Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts
at least one amino acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and
113-118 (inclusive); wherein the residues in contact are within six (6) angstroms or less
of the antibody, as determined by X-ray crystallography; optionally, wherein said
antibody blocks binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine
and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ ID: 40), but does not block
binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts
at least one amino acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and
113-118 (inclusive); wherein the residues in contact are within six (6) angstroms or less
of the antibody, as determined by X-ray crystallography; wherein the antibody further
contacts at least one residue of the following: 56-61 (inclusive), 107, 119-120 (inclusive) ,
and 122; optionally, wherein said antibody blocks binding of human Tim-3 (SEQ ID
NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human galectin-
9 (SEQ ID: 40), but does not block binding of human Tim-3 (SEQ ID NO:1) to human
CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts
amino acid residues 50, 55-65, 72, 107, 111, 113-120, and 122. An antibody that binds
human Tim-3 (SEQ ID NO:1), wherein the antibody contacts amino acid residues 50, 55-
65, 72, 107, 111, 113-120, and 122, as determined by X-ray crystallography. An
antibody that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts amino
acid residues 50, 55-65, 72, 107, 111, 113-120, and 122, as determined by X-ray
crystallography; optionally, wherein said antibody blocks binding of human Tim-3 (SEQ
ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human
galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3 (SEQ ID NO:1) to
human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts
at least one amino acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and
113-118 (inclusive); wherein the antibody contacts: at least two of the residues;
preferably at least three of the residues; more preferably at least four of the residues; more
preferably at least five of the residues; more preferably at least six of the residues; more
preferably at least seven of the residues; more preferably at least eight of the residues;
more preferably at least nine of the residues; more preferably at least ten of the residues;
more preferably at least eleven of the residues; more preferably at least twelve of the
residues; more preferably at least thirteen of the residues; or more preferably all of the
residues.
An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts
at least one amino acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and
113-118 (inclusive); wherein the antibody contacts: at least two of the residues;
preferably at least three of the residues; more preferably at least four of the residues; more
preferably at least five of the residues; more preferably at least six of the residues; more
preferably at least seven of the residues; more preferably at least eight of the residues;
more preferably at least nine of the residues; more preferably at least ten of the residues;
more preferably at least eleven of the residues; more preferably at least twelve of the
residues; more preferably at least thirteen of the residues; or more preferably all of the
residues; wherein said antibody blocks binding of human Tim-3 (SEQ ID NO:1) to
human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ
ID: 40), but does not block binding of human Tim-3 (SEQ ID NO:1) to human
CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts
at least one amino acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and
113-118 (inclusive); wherein the antibody contacts: at least two of the residues;
preferably at least three of the residues; more preferably at least four of the residues; more
preferably at least five of the residues; more preferably at least six of the residues; more
preferably at least seven of the residues; more preferably at least eight of the residues;
more preferably at least nine of the residues; more preferably at least ten of the residues;
more preferably at least eleven of the residues; more preferably at least twelve of the
residues; more preferably at least thirteen of the residues; or more preferably all of the
residues; wherein the residues in contact are within six (6) angstroms or less of the
antibody, as determined by X-ray crystallography.
An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts
at least one amino acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and
113-118 (inclusive); wherein the antibody contacts: at least two of the residues;
preferably at least three of the residues; more preferably at least four of the residues; more
preferably at least five of the residues; more preferably at least six of the residues; more
preferably at least seven of the residues; more preferably at least eight of the residues;
more preferably at least nine of the residues; more preferably at least ten of the residues;
more preferably at least eleven of the residues; more preferably at least twelve of the
residues; more preferably at least thirteen of the residues; or more preferably all of the
residues; wherein the residues in contact are within six (6) angstroms or less of the
antibody, as determined by X-ray crystallography; optionally, wherein said antibody
blocks binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human
Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ ID: 40), but does not block binding of
human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
The present invention provides an anti-human Tim-3 antibody, wherein the antibody
is glycosylated.
Also described is a DNA molecule comprising a polynucleotide sequence
encoding a polypeptide having the amino acid sequence of SEQ ID NO.10, 22, or 34.
Also described is a DNA molecule comprising a polynucleotide sequence encoding a
polypeptide having the amino acid sequence of SEQ ID NO. 11, 23, or 35. Also
described is a DNA molecule comprising a pair of polynucleotide sequences encoding
two distinct polypeptides having the amino acid sequence of SEQ ID NO. 10 and 11,
respectively; 22 and 23, respectively; or 34 and 35, respectively.
Also described is a DNA molecule comprising a polynucleotide sequence
encoding a polypeptide having the amino acid sequence of SEQ ID NO. 10, 22, or 34,
wherein the polynucleotide sequence comprises SEQ ID NO. 12, 24, or 36, respectively.
Also described is a DNA molecule comprising a polynucleotide sequence encoding a
polypeptide having the amino acid sequence of SEQ ID NO. 11, 23, or 35, wherein the
polynucleotide sequence comprises SEQ ID NO.13, 25, or 37, respectively.
In another aspect, the invention provides an isolated mammalian cell expressing an
antibody comprising a heavy chain (HC) and a light chain (LC), wherein:
a. the HC has the amino acid sequence of SEQ ID NO: 10 and the LC has the
amino acid sequence of SEQ ID NO: 11;
b. the HC has the amino acid sequence of SEQ ID NO: 22 and the LC has the
amino acid sequence of SEQ ID NO: 23; or
c. the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the
amino acid sequence of SEQ ID NO: 35.
Also described is a mammalian cell capable of expressing an antibody comprising
a heavy chain (HC) and a light chain (LC), wherein the HC and the LC have the amino
acid sequences given in SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or
34 and 35, respectively.
Also described is a mammalian cell capable of expressing an antibody comprising
a heavy chain (HC) and a light chain (LC), wherein the HC has the amino acid sequence
of SEQ ID NO: 10 and the LC has the amino acid sequence of SEQ ID NO: 11.
Also described is a mammalian cell capable of expressing an antibody comprising
a heavy chain (HC) and a light chain (LC), wherein the HC has the amino acid sequence
of SEQ ID NO: 22 and the LC has the amino acid sequence of SEQ ID NO: 23.
Also described is a mammalian cell capable of expressing an antibody comprising
a heavy chain (HC) and a light chain (LC), wherein the HC has the amino acid sequence
of SEQ ID NO: 34 and the LC has the amino acid sequence of SEQ ID NO: 35.
In another aspect, the invention provides an in vitro process for producing an antibody
comprising cultivating a mammalian cell capable of expressing the antibody and
recovering the antibody; wherein the antibody comprises a heavy chain (HC) and a light
chain (LC),wherein:
a. the HC has the amino acid sequence of SEQ ID NO: 10 and the LC has the
amino acid sequence of SEQ ID NO: 11;
b. the HC has the amino acid sequence of SEQ ID NO: 22 and the LC has the
amino acid sequence of SEQ ID NO: 23; or
c. the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the
amino acid sequence of SEQ ID NO: 35.
Also described is a process for producing an antibody comprising cultivating a
mammalian cell capable of expressing the antibody and recovering the antibody; wherein
the antibody comprises a heavy chain and a light chain having the amino acid sequences
given in SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35,
respectively.
Also described is a process for producing an antibody comprising cultivating a
mammalian cell capable of expressing the antibody and recovering the antibody; wherein
the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 10
and a light chain having the amino acid sequence of SEQ ID NO: 11.
Also described is a process for producing an antibody comprising cultivating a
mammalian cell capable of expressing the antibody and recovering the antibody; wherein
the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 22
and a light chain having the amino acid sequences of SEQ ID NO: 23.
Also described is a process for producing an antibody comprising cultivating a
mammalian cell capable of expressing the antibody and recovering the antibody; wherein
the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 34
and a light chain having the amino acid sequence of SEQ ID NO: 35.
Also described is an anti-human Tim-3 antibody disclosed herein produced by a
process of the present invention.
In another aspect, the present invention provides a pharmaceutical composition,
comprising an anti-human Tim-3 antibody of the present invention, and an acceptable
carrier, diluent, or excipient.
In another aspect, the present invention relates to use of an antibody of the
invention in the manufacture of a medicament for treating cancer.
Also described is a method of treating cancer, comprising administering to a
patient in need, thereof an effective amount of an anti-human Tim-3 antibody of the
present invention.
In some embodiments, described is a method of treating cancer, comprising
administering to a patient in need, thereof an effective amount of an anti-human Tim-3
antibody, wherein the cancer is melanoma, lung cancer, non-small cell lung cancer, head
and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer,
bladder cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft
tissue sarcoma, or liver cancer.
In some embodiments, described is a method of treating cancer, comprising
administering to a patient in need, thereof an effective amount of an anti-human Tim-3
antibody, wherein the cancer is melanoma, lung cancer, non-small cell lung cancer, head
and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer,
bladder cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft
tissue sarcoma, or liver cancer; wherein the the antibody comprises a HCDR1, HCDR2,
HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences shown in
SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or
26, 27, 28, 29, 30, and 31, respectively.
In some embodiments, described is a method of treating cancer, comprising
administering to a patient in need, thereof an effective amount of an anti-human Tim-3
antibody, wherein the cancer is melanoma, lung cancer, non-small cell lung cancer, head
and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer,
bladder cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft
tissue sarcoma, or liver cancer; wherein the the antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC comprises a heavy chain variable region (HCVR)
and the LC comprises a light chain variable region (LCVR), wherein: the HCVR has the
amino acid sequence of SEQ ID NO: 8, and the LCVR has the amino acid sequence of
SEQ ID NO: 9; the HCVR has the amino acid sequence of SEQ ID NO: 20, and the
LCVR has the amino acid sequence of SEQ ID NO: 21; or the HCVR has the amino acid
sequence of SEQ ID NO: 32, and the LCVR has the amino acid sequence of SEQ ID NO:
33.
In some embodiments, described is a method of treating cancer, comprising
administering to a patient in need, thereof an effective amount of an anti-human Tim-3
antibody, wherein the cancer is melanoma, lung cancer, non-small cell lung cancer, head
and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer,
bladder cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft
tissue sarcoma, or liver cancer; wherein the the antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
Also described is a method of treating cancer, comprising administering to a
patient in need, thereof an effective amount of an anti-human Tim-3 antibody of the
present invention, wherein the cancer is melanoma. Also described is a method of
treating cancer, comprising administering to a patient in need, thereof an effective amount
of an anti-human Tim-3 antibody of the present invention, wherein the cancer is lung
cancer. Also described isa method of treating cancer, comprising administering to a
patient in need, thereof an effective amount of an anti-human Tim-3 antibody of the
present invention, wherein the lung cancer is non-small cell lung cancer. Also described
is a method of treating cancer, comprising administering to a patient in need, thereof an
effective amount of an anti-human Tim-3 antibody of the present invention, wherein the
cancer is head and neck cancer. Also described is a method of treating cancer,
comprising administering to a patient in need, thereof an effective amount of an anti-
human Tim-3 antibody of the present invention, wherein the cancer is colorectal cancer.
Also described isa method of treating cancer, comprising administering to a patient in
need, thereof an effective amount of an anti-human Tim-3 antibody of the present
invention, wherein the cancer is pancreatic cancer. Also described isa method of treating
cancer, comprising administering to a patient in need, thereof an effective amount of an
anti-human Tim-3 antibody of the present invention, wherein the cancer is gastric cancer.
Also described isa method of treating cancer, comprising administering to a patient in
need, thereof an effective amount of an anti-human Tim-3 antibody of the present
invention, wherein the cancer is kidney cancer. Also described isa method of treating
cancer, comprising administering to a patient in need, thereof an effective amount of an
anti-human Tim-3 antibody of the present invention, wherein the cancer is bladder cancer.
Also described isa method of treating cancer, comprising administering to a patient in
need, thereof an effective amount of an anti-human Tim-3 antibody of the present
invention, wherein the cancer is prostate cancer. Also described isa method of treating
cancer, comprising administering to a patient in need, thereof an effective amount of an
anti-human Tim-3 antibody of the present invention, wherein the cancer is breast cancer.
Also described is a method of treating cancer, comprising administering to a patient in
need, thereof an effective amount of an anti-human Tim-3 antibody of the present
invention, wherein the cancer is ovarian cancer. Also described isa method of treating
cancer, comprising administering to a patient in need, thereof an effective amount of an
anti-human Tim-3 antibody of the present invention, wherein the cancer is esophageal
cancer. Also described isa method of treating cancer, comprising administering to a
patient in need, thereof an effective amount of an anti-human Tim-3 antibody of the
present invention, wherein the cancer is soft tissue sarcoma. Also described isa method
of treating cancer, comprising administering to a patient in need, thereof an effective
amount of an anti-human Tim-3 antibody of the present invention, wherein the cancer is
liver cancer.
In some embodiments, the methods comprise the administration of an effective
amount of an anti-human Tim-3 antibody of the present invention in simultaneous,
separate, or sequential combination with one or more chemotherapeutic agents. Non-
limiting examples of chemotherapeutic agents include 5-fluorouracil, hydroxyurea,
gemcitabine, methotrexate, pemetrexed, doxorubicin, etoposide, cetuximab, carboplatin,
cisplatin, cyclophosphamide, melphalan, dacarbazine, taxol, camptothecin, FOLFIRI,
docetaxel, daunorubicin, paclitaxel, oxaliplatin, and combinations thereof. In some
embodiments, the methods comprise the administration of an effective amount of an anti-
human Tim-3 antibody of the present invention in simultaneous, separate, or sequential
combination with ionizing radiation.
Also described is an anti-human Tim-3 antibody, for use in therapy. Also
described is an anti-human Tim-3 antibody, for use in therapy; wherein the anti-human
Tim-3 antibody binds human Tim-3 (SEQ ID NO: 1) and comprises HCDR1, HCDR2,
HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences shown in
SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or
26, 27, 28, 29, 30, and 31, respectively. Also described is an anti-human Tim-3 antibody,
for use in therapy; wherein the anti-human Tim-3 antibody binds human Tim-3 (SEQ ID
NO: 1) and comprises HCDR1 having the amino acid sequence of SEQ ID NO: 2,
HCDR2 having the amino acid sequence of SEQ ID NO: 3, HCDR3 having the amino
acid sequence of SEQ ID NO: 4, LCDR1 having the amino acid sequence of SEQ ID NO:
, LCDR2 having the amino acid sequence of SEQ ID NO: 6, and LCDR3 having the
amino acid sequence of SEQ ID NO: 7. Also described is an anti-human Tim-3 antibody,
for use in therapy; wherein the anti-human Tim-3 antibody binds human Tim-3 and
comprises HCDR1 having the amino acid sequence of SEQ ID NO: 14, HCDR2 having
the amino acid sequence of SEQ ID NO: 15, HCDR3 having the amino acid sequence of
SEQ ID NO: 16, LCDR1 having the amino acid sequence of SEQ ID NO: 17, LCDR2
having the amino acid sequence of SEQ ID NO: 18, and LCDR3 having the amino acid
sequence of SEQ ID NO: 19. Also described is an anti-human Tim-3 antibody, for use in
therapy; wherein the anti-human Tim-3 antibody binds human Tim-3 (SEQ ID NO: 1)
and comprises a HCDR1 having the amino acid sequence of SEQ ID NO: 26, HCDR2
having the amino acid sequence of SEQ ID NO: 27, HCDR3 having the amino acid
sequence of SEQ ID NO: 28, LCDR1 having the amino acid sequence of SEQ ID NO: 29,
LCDR2 having the amino acid sequence of SEQ ID NO: 30, and LCDR3 having the
amino acid sequence of SEQ ID NO: 31.
Also described is an anti-human Tim-3 antibody, for use in therapy; wherein the
anti-human Tim-3 antibody binds human Tim-3 (SEQ ID NO: 1) and comprises a heavy
chain (HC) and a light chain (LC), wherein the HC comprises a heavy chain variable
region (HCVR) and the LC comprises a light chain variable region (LCVR), wherein: the
HCVR has the amino acid sequence of SEQ ID NO: 8, and the LCVR has the amino acid
sequence of SEQ ID NO: 9; the HCVR has the amino acid sequence of SEQ ID NO: 20,
and the LCVR has the amino acid sequence of SEQ ID NO: 21; or the HCVR has the
amino acid sequence of SEQ ID NO: 32, and the LCVR has the amino acid sequence of
SEQ ID NO: 33. Also described is an anti-human Tim-3 antibody, for use in therapy;
wherein the anti-human Tim-3 antibody binds human Tim-3 (SEQ ID NO: 1) and
comprises a heavy chain (HC) and a light chain (LC), wherein the HC comprises a heavy
chain variable region (HCVR) and the LC comprises a light chain variable region
(LCVR), wherein: the HCVR has the amino acid sequence of SEQ ID NO: 8, and the
LCVR has the amino acid sequence of SEQ ID NO: 9. Also described is an anti-human
Tim-3 antibody, for use in therapy; wherein the anti-human Tim-3 antibody binds human
Tim-3 (SEQ ID NO: 1) and comprises a heavy chain (HC) and a light chain (LC),
wherein the HC comprises a heavy chain variable region (HCVR) and the LC comprises a
light chain variable region (LCVR), wherein: the HCVR has the amino acid sequence of
SEQ ID NO: 20, and the LCVR has the amino acid sequence of SEQ ID NO: 21. Also
described is an anti-human Tim-3 antibody, for use in therapy; wherein the anti-human
Tim-3 antibody binds human Tim-3 (SEQ ID NO: 1) and comprises a heavy chain (HC)
and a light chain (LC), wherein the HC comprises a heavy chain variable region (HCVR)
and the LC comprises a light chain variable region (LCVR), wherein: the HCVR has the
amino acid sequence of SEQ ID NO: 32, and the LCVR has the amino acid sequence of
SEQ ID NO: 33.
Also described is an anti-human Tim-3 antibody, for use in therapy; wherein the
anti-human Tim-3antibody binds human Tim-3 (SEQ ID NO: 1) and comprises a heavy
chain (HC) and a light chain (LC), wherein the HC and the LC have the amino acid
sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35,
respectively. Also described is an anti-human Tim-3 antibody, for use in therapy;
wherein the anti-human Tim-3 antibody binds human Tim-3 (SEQ ID NO: 1) and
comprises a heavy chain (HC) and a light chain (LC), wherein the HC has the amino acid
sequence of SEQ ID NO: 10 and the LC has the amino acid sequence of SEQ ID NO: 11.
Also described is an anti-human Tim-3 antibody, for use in therapy; wherein the anti-
human Tim-3 antibody binds human Tim-3 (SEQ ID NO: 1) and comprises a heavy chain
(HC) and a light chain (LC), wherein the HC has the amino acid sequence of SEQ ID NO:
22 and the LC has the amino acid sequence of SEQ ID NO: 23. Also described is an
anti-human Tim-3 antibody, for use in therapy; wherein the anti-human Tim-3 antibody
binds human Tim-3 (SEQ ID NO: 1) and comprises a heavy chain (HC) and a light chain
(LC), wherein the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the
amino acid sequence of SEQ ID NO: 35.
Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer. Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3,
LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences shown in SEQ ID
NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27,
28, 29, 30, and 31, respectively. Also described is an anti-human Tim-3 antibody, for use
in the treatment of cancer; wherein the anti-human Tim-3 antibody comprises HCDR1
having the amino acid sequence of SEQ ID NO: 2, HCDR2 having the amino acid
sequence of SEQ ID NO: 3, HCDR3 having the amino acid sequence of SEQ ID NO: 4,
LCDR1 having the amino acid sequence of SEQ ID NO: 5, LCDR2 having the amino
acid sequence of SEQ ID NO: 6, and LCDR3 having the amino acid sequence of SEQ ID
NO: 7. Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer; wherein the anti-human Tim-3 antibody comprises HCDR1 having the amino acid
sequence of SEQ ID NO: 14, HCDR2 having the amino acid sequence of SEQ ID NO:
, HCDR3 having the amino acid sequence of SEQ ID NO: 16, LCDR1 having the
amino acid sequence of SEQ ID NO:17, LCDR2 having the amino acid sequence of SEQ
ID NO: 18, and LCDR3 having the amino acid sequence of SEQ ID NO: 19. Also
described is an anti-human Tim-3 antibody, for use in the treatment of cancer; wherein
the anti-human Tim-3 antibody comprises HCDR1 having the amino acid sequence of
SEQ ID NO: 26, HCDR2 having the amino acid sequence of SEQ ID NO: 27, HCDR3
having the amino acid sequence of SEQ ID NO: 28, LCDR1 having the amino acid
sequence of SEQ ID NO: 29, LCDR2 having the amino acid sequence of SEQ ID NO: 30,
and LCDR3 having the amino acid sequence of SEQ ID NO: 31.
Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light
chain (LC), wherein the HC comprises a heavy chain variable region (HCVR) and the LC
comprises a light chain variable region (LCVR), wherein: the HCVR has the amino acid
sequence of SEQ ID NO: 8, and the LCVR has the amino acid sequence of SEQ ID NO:
9; the HCVR has the amino acid sequence of SEQ ID NO: 20, and the LCVR has the
amino acid sequence of SEQ ID NO: 21; or the HCVR has the amino acid sequence of
SEQ ID NO: 32, and the LCVR has the amino acid sequence of SEQ ID NO: 33. Also
described is an anti-human Tim-3 antibody, for use in the treatment of cancer; wherein
the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC),
wherein the HC comprises a heavy chain variable region (HCVR) and the LC comprises a
light chain variable region (LCVR), wherein: the HCVR has the amino acid sequence of
SEQ ID NO: 8, and the LCVR has the amino acid sequence of SEQ ID NO: 9. Also
described is an anti-human Tim-3 antibody, for use in the treatment of cancer; wherein
the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC),
wherein the HC comprises a heavy chain variable region (HCVR) and the LC comprises a
light chain variable region (LCVR), wherein: the HCVR has the amino acid sequence of
SEQ ID NO: 20, and the LCVR has the amino acid sequence of SEQ ID NO: 21. Also
described is an anti-human Tim-3 antibody, for use in the treatment of cancer; wherein
the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC),
wherein the HC comprises a heavy chain variable region (HCVR) and the LC comprises a
light chain variable region (LCVR), wherein: the HCVR has the amino acid sequence of
SEQ ID NO: 32, and the LCVR has the amino acid sequence of SEQ ID NO: 33.
Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light
chain (LC), wherein the HC and the LC have the amino acid sequences given in SEQ ID
NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively. Also
described is an anti-human Tim-3 antibody, for use in the treatment of cancer; wherein
the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC),
wherein the HC has the amino acid sequence of SEQ ID NO: 10 and the LC has the
amino acid sequence of SEQ ID NO: 11. Also described is an anti-human Tim-3
antibody, for use in the treatment of cancer; wherein the anti-human Tim-3 antibody
comprises a heavy chain (HC) and a light chain (LC), wherein the HC has the amino acid
sequence of SEQ ID NO: 22 and the LC has the amino acid sequence of SEQ ID NO: 23.
Also described is an anti-human Tim-3 antibody, for use in the treatment of cancer;
wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light chain
(LC), wherein the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the
amino acid sequence of SEQ ID NO:35.
Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is melanoma, lung cancer, non-small cell lung cancer, head
and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer,
bladder cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft
tissue sarcoma, or liver cancer.
Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is melanoma, lung cancer, non-small cell lung cancer, head
and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer,
bladder cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft
tissue sarcoma, or liver cancer; wherein the anti-human Tim-3 antibody comprises a
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid
sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19,
respectively; or 26, 27, 28, 29, 30, and 31, respectively. Also described is an anti-human
Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is melanoma, lung
cancer, non-small cell lung cancer, head and neck cancer, colorectal cancer, pancreatic
cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer,
ovarian cancer, esophageal cancer, soft tissue sarcoma, or liver cancer; wherein the anti-
human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC), wherein the
HC comprises a heavy chain variable region (HCVR) and the LC comprises a light chain
variable region (LCVR), wherein: the HCVR has the amino acid sequence of SEQ ID
NO: 8, and the LCVR has the amino acid sequence of SEQ ID NO: 9; the HCVR has the
amino acid sequence of SEQ ID NO: 20, and the LCVR has the amino acid sequence of
SEQ ID NO: 21; or the HCVR has the amino acid sequence of SEQ ID NO: 32, and the
LCVR has the amino acid sequence of SEQ ID NO: 33. Also described is an anti-human
Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is melanoma, lung
cancer, non-small cell lung cancer, head and neck cancer, colorectal cancer, pancreatic
cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer,
ovarian cancer, esophageal cancer, soft tissue sarcoma, or liver cancer; wherein the anti-
human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC), wherein the
HC and the LC have the amino acid sequences of SEQ ID NOs: 10 and 11, respectively;
22 and 23, respectively; or 34 and 35, respectively.
Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is melanoma. Also described is an anti-human Tim-3
antibody, for use in the treatment of cancer, wherein the cancer is lung cancer. Also
described is an anti-human Tim-3 antibody for use in the treatment of lung cancer,
wherein the lung cancer is non-small cell lung cancer. Also described is an anti-human
Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is head and neck
cancer. Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is colorectal cancer. Also described is an anti-human Tim-3
antibody, for use in the treatment of cancer, wherein the cancer is pancreatic cancer. Also
described is an anti-human Tim-3 antibody, for use in the treatment of cancer, wherein
the cancer is gastric cancer. Also described is an anti-human Tim-3, for use in the
treatment of cancer, wherein the cancer is kidney cancer. Also described is an anti-
human Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is bladder
cancer. Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is prostate cancer. Also described is an anti-human Tim-3
antibody, for use in the treatment of cancer, wherein the cancer is breast cancer. Also
described is an anti-human Tim-3 antibody, for use in the treatment of cancer, wherein
the cancer is ovarian cancer. Also described is an anti-human Tim-3 antibody, for use in
the treatment of cancer, wherein the cancer is esophageal cancer. Also described is an
anti-human Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is soft
tissue sarcoma. Also described is an anti-human Tim-3 antibody, for use in the treatment
of cancer, wherein the cancer is liver cancer.
Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is melanoma; wherein the anti-human Tim-3 antibody
comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the
amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17,
18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively. Also described is an
anti-human Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is lung
cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3,
LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2,
3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29,
, and 31, respectively. Also described is an anti-human Tim-3 antibody for use in the
treatment of lung cancer, wherein the lung cancer is non-small cell lung cancer; wherein
the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2,
and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7,
respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31,
respectively. Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is head and neck cancer; wherein the anti-human Tim-3
antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting
of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16,
17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively. Also described is
an anti-human Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is
colorectal cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2,
HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ
ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26,
27, 28, 29, 30, and 31, respectively. Also described is an anti-human Tim-3 antibody, for
use in the treatment of cancer, wherein the cancer is pancreatic cancer; wherein the anti-
human Tim-3 antibody comprises a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and
LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7,
respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31,
respectively. Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is gastric cancer; wherein the anti-human Tim-3 antibody
comprises a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the
amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17,
18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively. Also described is an
anti-human Tim-3, for use in the treatment of cancer, wherein the cancer is kidney cancer;
wherein the anti-human Tim-3 antibody comprises a HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. Also described is an anti-human Tim-3 antibody, for use in the
treatment of cancer, wherein the cancer is bladder cancer; wherein the anti-human Tim-3
antibody comprises a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3
consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively;
14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively. Also
described is an anti-human Tim-3 antibody, for use in the treatment of cancer, wherein
the cancer is prostate cancer; wherein the anti-human Tim-3 antibody comprises a
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid
sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19,
respectively; or 26, 27, 28, 29, 30, and 31, respectively. Also described is an anti-human
Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is breast cancer;
wherein the anti-human Tim-3 antibody comprises a HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. Also described is an anti-human Tim-3 antibody, for use in the
treatment of cancer, wherein the cancer is ovarian cancer; wherein the anti-human Tim-3
antibody comprises a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3
consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively;
14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively. Also
described is an anti-human Tim-3 antibody, for use in the treatment of cancer, wherein
the cancer is esophageal cancer; wherein the anti-human Tim-3 antibody comprises a
HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid
sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19,
respectively; or 26, 27, 28, 29, 30, and 31, respectively. Also described is an anti-human
Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is soft tissue
sarcoma; wherein the anti-human Tim-3 antibody comprises a HCDR1, HCDR2,
HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ
ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26,
27, 28, 29, 30, and 31, respectively. Also described is an anti-human Tim-3 antibody, for
use in the treatment of cancer, wherein the cancer is liver cancer; wherein the anti-human
Tim-3 antibody comprises a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3
consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively;
14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively.
Also described is ides an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is melanoma; wherein the anti-human Tim-3 antibody
comprises a heavy chain (HC) and a light chain (LC), wherein the HC and the LC have
the amino acid sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23,
respectively; or 34 and 35, respectively. Also described is an anti-human Tim-3 antibody,
for use in the treatment of cancer, wherein the cancer is lung cancer; wherein the anti-
human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC), wherein the
HC and the LC have the amino acid sequences of SEQ ID NOs: 10 and 11, respectively;
22 and 23, respectively; or 34 and 35, respectively. Also described is an anti-human Tim-
3 antibody for use in the treatment of lung cancer, wherein the lung cancer is non-small
cell lung cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
Also described is an anti-human Tim-3 antibody, for use in the treatment of cancer,
wherein the cancer is head and neck cancer; wherein the anti-human Tim-3 antibody
comprises a heavy chain (HC) and a light chain (LC), wherein the HC and the LC have
the amino acid sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23,
respectively; or 34 and 35, respectively. Also described is an anti-human Tim-3 antibody,
for use in the treatment of cancer, wherein the cancer is colorectal cancer; wherein the
anti-human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC),
wherein the HC and the LC have the amino acid sequences of SEQ ID NOs: 10 and 11,
respectively; 22 and 23, respectively; or 34 and 35, respectively. Also described is an
anti-human Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is
pancreatic cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
Also described is an anti-human Tim-3 antibody, for use in the treatment of cancer,
wherein the cancer is gastric cancer; wherein the anti-human Tim-3 antibody comprises a
heavy chain (HC) and a light chain (LC), wherein the HC and the LC have the amino acid
sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35,
respectively. Also described is an anti-human Tim-3, for use in the treatment of cancer,
wherein the cancer is kidney cancer; wherein the anti-human Tim-3 antibody comprises a
heavy chain (HC) and a light chain (LC), wherein the HC and the LC have the amino acid
sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35,
respectively. Also described is an anti-human Tim-3 antibody, for use in the treatment of
cancer, wherein the cancer is bladder cancer; wherein the anti-human Tim-3 antibody
comprises a heavy chain (HC) and a light chain (LC), wherein the HC and the LC have
the amino acid sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23,
respectively; or 34 and 35, respectively. Also described is an anti-human Tim-3 antibody,
for use in the treatment of cancer, wherein the cancer is prostate cancer; wherein the anti-
human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC), wherein the
HC and the LC have the amino acid sequences of SEQ ID NOs: 10 and 11, respectively;
22 and 23, respectively; or 34 and 35, respectively. Also described is an anti-human Tim-
3 antibody, for use in the treatment of cancer, wherein the cancer is breast cancer;
wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light chain
(LC), wherein the HC and the LC have the amino acid sequences of SEQ ID NOs: 10 and
11, respectively; 22 and 23, respectively; or 34 and 35, respectively. Also described is an
anti-human Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is
ovarian cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
Also described is an anti-human Tim-3 antibody, for use in the treatment of cancer,
wherein the cancer is esophageal cancer; wherein the anti-human Tim-3 antibody
comprises a heavy chain (HC) and a light chain (LC), wherein the HC and the LC have
the amino acid sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23,
respectively; or 34 and 35, respectively. Also described is an anti-human Tim-3 antibody,
for use in the treatment of cancer, wherein the cancer is soft tissue sarcoma; wherein the
anti-human Tim-3 antibody comprises a heavy chain (HC) and a light chain (LC),
wherein the HC and the LC have the amino acid sequences of SEQ ID NOs: 10 and 11,
respectively; 22 and 23, respectively; or 34 and 35, respectively. Also described is an
anti-human Tim-3 antibody, for use in the treatment of cancer, wherein the cancer is liver
cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light
chain (LC), wherein the HC and the LC have the amino acid sequences of SEQ ID NOs:
and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
Also described is the an anti-human Tim-3 antibody for use in simultaneous,
separate, or sequential combination with one or more chemotherapeutic agents.
Also described is an anti-human Tim-3 antibody for use in simultaneous, separate,
or sequential combination with with one or more chemotherapeutic agents in the
treatment of cancer. Also described is an anti-human Tim-3 antibody for use in
simultaneous, separate, or sequential combination with with one or more
chemotherapeutic agents in the treatment of cancer; wherein the anti-human Tim-3
antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting
of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16,
17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively. Also described is
an anti-human Tim-3 antibody for use in simultaneous, separate, or sequential
combination with with one or more chemotherapeutic agents in the treatment of cancer;
wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light chain
(LC), wherein the HC and the LC have the amino acid sequences of SEQ ID NOs: 10 and
11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
Also described is an effective amount of an anti-human Tim-3 antibody for use in
simultaneous, separate, or sequential combination with ionizing radiation. Also described
is an effective amount of an anti-human Tim-3 antibody for use in simultaneous,
separate, or sequential combination with ionizing radiation in the treatment of cancer.
Also described is an effective amount of an anti-human Tim-3 antibody for use in
simultaneous, separate, or sequential combination with ionizing radiation in the treatment
of cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3,
LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences shown in SEQ ID
NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27,
28, 29, 30, and 31, respectively. Also described is an effective amount of an anti-human
Tim-3 antibody for use in simultaneous, separate, or sequential combination with ionizing
radiation in the treatment of cancer; wherein the anti-human Tim-3 antibody comprises a
heavy chain (HC) and a light chain (LC), wherein the HC and the LC have the amino acid
sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35,
respectively.
Also described is the use of an anti-human Tim-3 antibody for the manufacture of
a medicament for the treatment of cancer.
The present invention provides the use of an anti-human Tim-3 antibody for the
manufacture of a medicament for the treatment of cancer; wherein the anti-human Tim-3
antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting
of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16,
17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively. The present
invention provides the use of an anti-human Tim-3 antibody for the manufacture of a
medicament for the treatment of cancer; wherein the anti-human Tim-3 antibody
comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the
amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively. The present
invention provides the use of an anti-human Tim-3 antibody for the manufacture of a
medicament for the treatment of cancer; wherein the anti-human Tim-3 antibody
comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the
amino acid sequences of SEQ ID NOs: 14, 15, 16, 17, 18, and 19, respectively. The
present invention provides the use of an anti-human Tim-3 antibody for the manufacture
of a medicament for the treatment of cancer; wherein the anti-human Tim-3 antibody
comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the
amino acid sequences of SEQ ID NOs: 26, 27, 28, 29, 30, and 31, respectively.
The present invention provides the use of an anti-human Tim-3 antibody for the
manufacture of a medicament for the treatment of cancer; wherein the anti-human Tim-3
antibody comprises a heavy chain (HC) and a light chain (LC), wherein the HC comprises
a heavy chain variable region (HCVR) and the LC comprises a light chain variable region
(LCVR), wherein: the HCVR has the amino acid sequence of SEQ ID NO: 8, and the
LCVR has the amino acid sequence of SEQ ID NO: 9; the HCVR has the amino acid
sequence of SEQ ID NO: 20, and the LCVR has the amino acid sequence of SEQ ID NO:
21; or the HCVR has the amino acid sequence of SEQ ID NO: 32, and the LCVR has the
amino acid sequence of SEQ ID NO: 33. The present invention provides the use of an
anti-human Tim-3 antibody for the manufacture of a medicament for the treatment of
cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light
chain (LC), wherein the HC comprises a heavy chain variable region (HCVR) and the LC
comprises a light chain variable region (LCVR), wherein: the HCVR has the amino acid
sequence of SEQ ID NO: 8, and the LCVR has the amino acid sequence of SEQ ID NO:
9. The present invention provides the use of an anti-human Tim-3 antibody for the
manufacture of a medicament for the treatment of cancer; wherein the anti-human Tim-3
antibody comprises a heavy chain (HC) and a light chain (LC), wherein the HC comprises
a heavy chain variable region (HCVR) and the LC comprises a light chain variable region
(LCVR), wherein: the HCVR has the amino acid sequence of SEQ ID NO: 20, and the
LCVR has the amino acid sequence of SEQ ID NO: 21. The present invention provides
the use of an anti-human Tim-3 antibody for the manufacture of a medicament for the
treatment of cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain
(HC) and a light chain (LC), wherein the HC comprises a heavy chain variable region
(HCVR) and the LC comprises a light chain variable region (LCVR), wherein: the HCVR
has the amino acid sequence of SEQ ID NO: 32, and the LCVR has the amino acid
sequence of SEQ ID NO: 33.
The present invention provides the use of an anti-human Tim-3 antibody for the
manufacture of a medicament for the treatment of cancer; wherein the anti-human Tim-3
antibody comprises a heavy chain (HC) and a light chain (LC), wherein the HC and the
LC have the amino acid sequences given in SEQ ID NOs: 10 and 11, respectively; 22 and
23, respectively; or 34 and 35, respectively. The present invention provides the use of an
anti-human Tim-3 antibody for the manufacture of a medicament for the treatment of
cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a light
chain (LC), wherein the HC has the amino acid sequence of SEQ ID NO: 10 and the LC
has the amino acid sequence of SEQ ID NO: 11. The present invention provides the use
of an anti-human Tim-3 antibody for the manufacture of a medicament for the treatment
of cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a
light chain (LC), wherein the HC has the amino acid sequence of SEQ ID NO: 22 and the
LC has the amino acid sequence of SEQ ID NO:23. The present invention provides the
use of an anti-human Tim-3 antibody for the manufacture of a medicament for the
treatment of cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain
(HC) and a light chain (LC), wherein the HC has the amino acid sequence of SEQ ID NO:
34 and the LC has the amino acid sequence of SEQ ID NO: 35.
Also described is the use of an anti-human Tim-3 antibody for the manufacture
of a medicament for the treatment of cancer, wherein the cancer is melanoma, lung
cancer, non-small cell lung cancer , head and neck cancer, colorectal cancer, pancreatic
cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer,
ovarian cancer, esophageal cancer, soft tissue sarcoma, or liver cancer. In a further
embodiment, the present invention provides the use of an anti-human Tim-3 antibody for
the manufacture of a medicament for the treatment of cancer, wherein the cancer is
melanoma, lung cancer, non-small cell lung cancer , head and neck cancer, colorectal
cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer,
breast cancer, ovarian cancer, esophageal cancer, soft tissue sarcoma, or liver cancer;
wherein the anti-Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2,
and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7,
respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31,
respectively. In a further embodiment, the present invention provides the use of an anti-
human Tim-3 antibody for the manufacture of a medicament for the treatment of cancer,
wherein the cancer is melanoma, lung cancer, non-small cell lung cancer , head and neck
cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer,
prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft tissue sarcoma, or
liver cancer; wherein the anti-Tim-3 antibody comprises a heavy chain (HC) and a light
chain (LC), wherein the HC comprises a heavy chain variable region (HCVR) and the LC
comprises a light chain variable region (LCVR), wherein: the HCVR has the amino acid
sequence of SEQ ID NO: 8, and the LCVR has the amino acid sequence of SEQ ID NO:
9; the HCVR has the amino acid sequence of SEQ ID NO: 20, and the LCVR has the
amino acid sequence of SEQ ID NO: 21; or the HCVR has the amino acid sequence of
SEQ ID NO: 32, and the LCVR has the amino acid sequence of SEQ ID NO: 33. In a
further embodiment, the present invention provides the use of an anti-human Tim-3
antibody for the manufacture of a medicament for the treatment of cancer, wherein the
cancer is melanoma, lung cancer, non-small cell lung cancer , head and neck cancer,
colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer,
prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft tissue sarcoma, or
liver cancer; wherein the anti-Tim-3 antibody comprises a heavy chain (HC) and a light
chain (LC), wherein the HC and the LC have the amino acid sequences given in SEQ ID
NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of melanoma;
wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
melanoma; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a
light chain (LC), wherein the HC and the LC have the amino acid sequences of SEQ ID
NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of lung cancer;
wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
lung cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a
light chain (LC), wherein the HC and the LC have the amino acid sequences of SEQ ID
NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of non-small cell
lung cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2,
HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ
ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26,
27, 28, 29, 30, and 31, respectively. The present invention provides the use of an anti-
human Tim-3 antibody of the present invention in the manufacture of a medicament for
the treatment of non-small cell lung cancer; wherein the anti-human Tim-3 antibody
comprises a heavy chain (HC) and a light chain (LC), wherein the HC and the LC have
the amino acid sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23,
respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of head and neck
cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3,
LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2,
3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29,
, and 31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
head and neck cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain
(HC) and a light chain (LC), wherein the HC and the LC have the amino acid sequences
of SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35,
respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of colorectal
cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3,
LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2,
3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29,
30, and 31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
colorectal cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of pancreatic
cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3,
LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2,
3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29,
30, and 31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
pancreatic cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of gastric cancer;
wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
gastric cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and
a light chain (LC), wherein the HC and the LC have the amino acid sequences of SEQ ID
NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of kidney cancer;
wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
kidney cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of bladder cancer;
wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
bladder cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of prostate
cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3,
LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2,
3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29,
30, and 31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
prostate cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of breast cancer;
wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
breast cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and
a light chain (LC), wherein the HC and the LC have the amino acid sequences of SEQ ID
NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of ovarian cancer;
wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
ovarian cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC)
and a light chain (LC), wherein the HC and the LC have the amino acid sequences of
SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of esophageal
cancer; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3,
LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2,
3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29,
30, and 31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
esophageal cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain
(HC) and a light chain (LC), wherein the HC and the LC have the amino acid sequences
of SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35,
respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of soft tissue
sarcoma; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3,
LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2,
3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29,
, and 31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
soft tissue sarcoma; wherein the anti-human Tim-3 antibody comprises a heavy chain
(HC) and a light chain (LC), wherein the HC and the LC have the amino acid sequences
of SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35,
respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of liver cancer;
wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1,
LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5,
6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and
31, respectively. The present invention provides the use of an anti-human Tim-3
antibody of the present invention in the manufacture of a medicament for the treatment of
liver cancer; wherein the anti-human Tim-3 antibody comprises a heavy chain (HC) and a
light chain (LC), wherein the HC and the LC have the amino acid sequences of SEQ ID
NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35, respectively.
The present invention provides the use of an anti-human Tim-3 antibody of the
present invention in the manufacture of a medicament for the treatment of cancer wherein
said medicament is to be administered simultaneously, separately, or sequentially with
one or more chemotherapeutic agents. The present invention provides the use of an anti-
human Tim-3 antibody of the present invention in the manufacture of a medicament for
the treatment of cancer wherein said medicament is to be administered simultaneously,
separately, or sequentially with one or more chemotherapeutic agents; wherein the anti-
Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3
consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively;
14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively. The
present invention provides the use of an anti-human Tim-3 antibody of the present
invention in the manufacture of a medicament for the treatment of cancer wherein said
medicament is to be administered simultaneously, separately, or sequentially with one or
more chemotherapeutic agents; wherein the anti-Tim-3 antibody comprises a heavy chain
(HC) and a light chain (LC), wherein the HC and the LC have the amino acid sequences
of SEQ ID NOs: 10 and 11, respectively; 22 and 23, respectively; or 34 and 35,
respectively.
Also described is the use of an effective amount of an anti-human Tim-3 antibody
for the manufacture of a medicament in simultaneous, separate, or sequential
combination with ionizing radiation. The present invention provides the use of an
effective amount of an anti-human Tim-3 antibody for the manufacture of a medicament
in simultaneous, separate, or sequential combination with ionizing radiation; wherein the
anti-Tim-3 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and
LCDR3 consisting of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7,
respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31,
respectively. The present invention provides the use of an effective amount of an anti-
human Tim-3 antibody for the manufacture of a medicament in simultaneous, separate,
or sequential combination with ionizing radiation; wherein the anti-Tim-3 antibody
comprises a heavy chain (HC) and a light chain (LC), wherein the HC and the LC have
the amino acid sequences of SEQ ID NOs: 10 and 11, respectively; 22 and 23,
respectively; or 34 and 35, respectively.
Also described is an anti-human Tim-3 antibody for use in the treatment of cancer,
wherein the anti-human Tim-3 antibody blocks binding of human Tim-3 (SEQ ID NO:1)
to human galectin-9 (SEQ ID: 40), preferably blocks binding of human Tim-3 (SEQ ID
NO:1) to phosphatidylserine, but does not block binding of human Tim-3 (SEQ ID NO:1)
to human CEACAM1 (SEQ ID: 39).
Also described is a monoclonal antibody that binds human Tim-3 (SEQ ID NO:1)
for use in therapy. Also described is a monoclonal antibody that binds human Tim-3
(SEQ ID NO:1) for use in the treatment of cancer. Also described is a monoclonal
antibody that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of cancer,
wherein said binding blocks binding of human Tim-3 (SEQ ID NO:1) to human
phosphatidylserine, but does not block binding of human Tim-3 (SEQ ID NO:1) to human
CEACAM1 (SEQ ID: 39). Also described is a monoclonal antibody that binds human
Tim-3 (SEQ ID NO:1) for use in the treatment of cancer, wherein said binding blocks
binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human
galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3 (SEQ ID NO:1) to
human CEACAM1 (SEQ ID: 39).
Also described is a monoclonal antibody that binds human Tim-3 (SEQ ID NO:1)
for use in simultaneous, separate, or sequential combination with one or more
chemotherapeutic agents in the treatment of cancer. Also described is a monoclonal
antibody that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of cancer,
wherein the cancer is melanoma, lung cancer, non-small cell lung cancer, head and neck
cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer,
prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft tissue sarcoma, or
liver cancer. Also described is a monoclonal antibody that binds an epitope of human
Tim-3 (SEQ ID NO:1) for use in simultaneous, separate, or sequential combination with
ionizing radiation in the treatment of cancer. Also described is a monoclonal antibody
that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of cancer. Also
described is a monoclonal antibody that binds human Tim-3 (SEQ ID NO:1) for use in
the treatment of cancer, wherein said binding blocks binding of human Tim-3 (SEQ ID
NO:1) to human phosphatidylserine, but does not block binding of human Tim-3 (SEQ ID
NO:1) to human CEACAM1 (SEQ ID: 39). Also described is a monoclonal antibody that
binds human Tim-3 (SEQ ID NO:1) (SEQ ID NO:1) for use in the treatment of cancer,
wherein said binding blocks binding of human Tim-3 (SEQ ID NO:1) to human
phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ ID: 40),
but does not block binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ
ID: 39).
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID
NO:1) for use in the treatment of cancer, wherein the antibody contacts residues 50, 55-
65, 72, 107, 111, 113-120, and 122. Also described is an antibody that binds an epitope
on human Tim-3 (SEQ ID NO:1) for use in the treatment of cancer, wherein the antibody
contacts residues 50, 55-65, 72, 107, 111, 113-120, and 122; wherein the epitope is
determined by X-ray crystallography and wherein the residues in contact are within six
(6) angstroms or less of the antibody; wherein said antibody blocks binding of human
Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to
human galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3 (SEQ ID
NO:1) to human CEACAM1 (SEQ ID: 39).
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID
NO:1) for use in the treatment of cancer, wherein the antibody contacts at least one
residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive).
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1) for
use in the treatment of cancer, wherein the antibody contacts at least one residue of the
following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive), wherein the
antibody contacts: at least two of the residues; preferably at least three of the residues;
more preferably at least four of the residues; more preferably at least five of the residues;
more preferably at least six of the residues; more preferably at least seven of the residues;
more preferably at least eight of the residues; more preferably at least nine of the
residues; more preferably at least ten of the residues; more preferably at least eleven of
the residues; more preferably at least twelve of the residues; more preferably at least
thirteen of the residues; or more preferably all of the residues.
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1)
for use in the treatment of cancer, wherein the antibody contacts at least one residue of
the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive); and wherein
the antibody further contacts at least one residue of the following: 56-61 (inclusive), 107,
119-120 (inclusive) , and 122. Also described is an antibody that binds an epitope on
human Tim-3 (SEQ ID NO:1) for use in the treatment of cancer, wherein the antibody
contacts at least one residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-
118 (inclusive), wherein the antibody contacts: at least two of the residues; preferably at
least three of the residues; more preferably at least four of the residues; more preferably at
least five of the residues; more preferably at least six of the residues; more preferably at
least seven of the residues; more preferably at least eight of the residues; more preferably
at least nine of the residues; more preferably at least ten of the residues; more preferably
at least eleven of the residues; more preferably at least twelve of the residues; more
preferably at least thirteen of the residues; or more preferably all of the residues; and
wherein the antibody further contacts at least one residue of the following: 56-61
(inclusive), 107, 119-120 (inclusive), and 122.
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1)
for use in the treatment of cancer, wherein the antibody contacts at least one residue of
the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive); and wherein
the antibody further contacts at least one residue of the following: 56-61 (inclusive), 107,
119-120 (inclusive) , and 122. Also described is an antibody that binds an epitope on
human Tim-3 (SEQ ID NO:1) for use in the treatment of cancer, wherein the antibody
contacts at least one residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-
118 (inclusive), wherein the antibody contacts: at least two of the residues; preferably at
least three of the residues; more preferably at least four of the residues; more preferably at
least five of the residues; more preferably at least six of the residues; more preferably at
least seven of the residues; more preferably at least eight of the residues; more preferably
at least nine of the residues; more preferably at least ten of the residues; more preferably
at least eleven of the residues; more preferably at least twelve of the residues; more
preferably at least thirteen of the residues; or more preferably all of the residues; and
wherein the antibody further contacts at least one residue of the following: 56-61
(inclusive), 107, 119-120 (inclusive), and 122.
Also described is an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1)
for use in the treatment of cancer, wherein the antibody contacts at least one residue of
the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive); wherein the
epitope is determined by X-ray crystallography and wherein the residues in contact are
within six (6) angstroms or less of the antibody; wherein said antibody blocks binding of
human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID
NO:1) to human galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3
(SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39); and optionally, wherein the
antibody further contacts at least one residue of the following: 56-61 (inclusive), 107,
119-120 (inclusive) , and 122. Also described is an antibody that binds an epitope on
human Tim-3 (SEQ ID NO:1) for use in the treatment of cancer, wherein the antibody
contacts at least one residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-
118 (inclusive), wherein the antibody contacts: at least two of the residues; preferably at
least three of the residues; more preferably at least four of the residues; more preferably at
least five of the residues; more preferably at least six of the residues; more preferably at
least seven of the residues; more preferably at least eight of the residues; more preferably
at least nine of the residues; more preferably at least ten of the residues; more preferably
at least eleven of the residues; more preferably at least twelve of the residues; more
preferably at least thirteen of the residues; or more preferably all of the residues; wherein
the epitope is determined by X-ray crystallography and wherein the residues in contact
are within six (6) angstroms or less of the antibody; wherein said antibody blocks binding
of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ
ID NO:1) to human galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3
(SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39); and optionally,wherein the antibody
further contacts at least one residue of the following: 56-61 (inclusive), 107, 119-120
(inclusive), and 122.
An antibody that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of
cancer, wherein the antibody contacts at least one amino acid residue of the following: 50,
55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive). An antibody that binds human
Tim-3 (SEQ ID NO:1) for use in the treatment of cancer, wherein the antibody contacts at
least one amino acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-
118 (inclusive); optionally, wherein said antibody blocks binding of human Tim-3 (SEQ
ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human
galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3 (SEQ ID NO:1) to
human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of
cancer, wherein the antibody contacts at least one amino acid residue of the following: 50,
55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive); wherein the residues in contact
are within six (6) angstroms or less of the antibody, as determined by X-ray
crystallography; optionally, wherein said antibody blocks binding of human Tim-3 (SEQ
ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human
galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3 (SEQ ID NO:1) to
human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of
cancer, wherein the antibody contacts at least one amino acid residue of the following: 50,
55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive); wherein the residues in contact
are within six (6) angstroms or less of the antibody, as determined by X-ray
crystallography; wherein the antibody further contacts at least one residue of the
following: 56-61 (inclusive), 107, 119-120 (inclusive) , and 122; optionally, wherein said
antibody blocks binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine
and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ ID: 40), but does not block
binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of
cancer, wherein the antibody contacts amino acid residues 50, 55-65, 72, 107, 111, 113-
120, and 122, as determined by X-ray crystallography. An antibody that binds human
Tim-3 (SEQ ID NO:1) ) for use in the treatment of cancer, wherein the antibody contacts
amino acid residues 50, 55-65, 72, 107, 111, 113-120, and 122, as determined by X-ray
crystallography; optionally, wherein said antibody blocks binding of human Tim-3 (SEQ
ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human
galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3 (SEQ ID NO:1) to
human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of
cancer, wherein the antibody contacts at least one amino acid residue of the following: 50,
55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive); wherein the antibody contacts: at
least two of the residues; preferably at least three of the residues; more preferably at least
four of the residues; more preferably at least five of the residues; more preferably at least
six of the residues; more preferably at least seven of the residues; more preferably at least
eight of the residues; more preferably at least nine of the residues; more preferably at
least ten of the residues; more preferably at least eleven of the residues; more preferably
at least twelve of the residues; more preferably at least thirteen of the residues; or more
preferably all of the residues.
An antibody that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of
cancer, wherein the antibody contacts at least one amino acid residue of the following: 50,
55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive); wherein the antibody contacts: at
least two of the residues; preferably at least three of the residues; more preferably at least
four of the residues; more preferably at least five of the residues; more preferably at least
six of the residues; more preferably at least seven of the residues; more preferably at least
eight of the residues; more preferably at least nine of the residues; more preferably at
least ten of the residues; more preferably at least eleven of the residues; more preferably
at least twelve of the residues; more preferably at least thirteen of the residues; or more
preferably all of the residues; wherein the residues in contact are within six (6) angstroms
or less of the antibody, as determined by X-ray crystallography.
An antibody that binds human Tim-3 (SEQ ID NO:1) for use in the treatment of
cancer, wherein the antibody contacts at least one amino acid residue of the following: 50,
55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive); wherein the antibody contacts: at
least two of the residues; preferably at least three of the residues; more preferably at least
four of the residues; more preferably at least five of the residues; more preferably at least
six of the residues; more preferably at least seven of the residues; more preferably at least
eight of the residues; more preferably at least nine of the residues; more preferably at
least ten of the residues; more preferably at least eleven of the residues; more preferably
at least twelve of the residues; more preferably at least thirteen of the residues; or more
preferably all of the residues; wherein the residues in contact are within six (6) angstroms
or less of the antibody, as determined by X-ray crystallography; optionally, wherein said
antibody blocks binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine
and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ ID: 40), but does not block
binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1) for the manufacture of a
medicament for the treatment of cancer, wherein the antibody contacts at least one amino
acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive).
An antibody that binds human Tim-3 (SEQ ID NO:1) for the manufacture of a
medicament for the treatment of cancer, wherein the antibody contacts at least one amino
acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive);
optionally, wherein said antibody blocks binding of human Tim-3 (SEQ ID NO:1) to
human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ
ID: 40), but does not block binding of human Tim-3 (SEQ ID NO:1) to human
CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1) for the manufacture of a
medicament for the treatment of cancer, wherein the antibody contacts at least one amino
acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive);
wherein the residues in contact are within six (6) angstroms or less of the antibody, as
determined by X-ray crystallography; optionally, wherein said antibody blocks binding of
human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID
NO:1) to human galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3
(SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1) for the manufacture of a
medicament for the treatment of cancer, wherein the antibody contacts at least one amino
acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive);
wherein the residues in contact are within six (6) angstroms or less of the antibody, as
determined by X-ray crystallography; wherein the antibody further contacts at least one
residue of the following: 56-61 (inclusive), 107, 119-120 (inclusive) , and 122; optionally,
wherein said antibody blocks binding of human Tim-3 (SEQ ID NO:1) to human
phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ ID: 40),
but does not block binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ
ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1) for the manufacture of a
medicament for the treatment of cancer, wherein the antibody contacts amino acid
residues 50, 55-65, 72, 107, 111, 113-120, and 122, as determined by X-ray
crystallography. An antibody that binds human Tim-3 (SEQ ID NO:1), wherein the
antibody contacts amino acid residues 50, 55-65, 72, 107, 111, 113-120, and 122, as
determined by X-ray crystallography; optionally, wherein said antibody blocks binding of
human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID
NO:1) to human galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3
(SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39).
An antibody that binds human Tim-3 (SEQ ID NO:1) for the manufacture of a
medicament for the treatment of cancer, wherein the antibody contacts at least one amino
acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive);
wherein the antibody contacts: at least two of the residues; preferably at least three of the
residues; more preferably at least four of the residues; more preferably at least five of the
residues; more preferably at least six of the residues; more preferably at least seven of the
residues; more preferably at least eight of the residues; more preferably at least nine of
the residues; more preferably at least ten of the residues; more preferably at least eleven
of the residues; more preferably at least twelve of the residues; more preferably at least
thirteen of the residues; or more preferably all of the residues.
An antibody that binds human Tim-3 (SEQ ID NO:1) for the manufacture of a
medicament for the treatment of cancer, wherein the antibody contacts at least one amino
acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive);
wherein the antibody contacts: at least two of the residues; preferably at least three of the
residues; more preferably at least four of the residues; more preferably at least five of the
residues; more preferably at least six of the residues; more preferably at least seven of the
residues; more preferably at least eight of the residues; more preferably at least nine of
the residues; more preferably at least ten of the residues; more preferably at least eleven
of the residues; more preferably at least twelve of the residues; more preferably at least
thirteen of the residues; or more preferably all of the residues; wherein the residues in
contact are within six (6) angstroms or less of the antibody, as determined by X-ray
crystallography.
An antibody that binds human Tim-3 (SEQ ID NO:1) for the manufacture of a
medicament for the treatment of cancer, wherein the antibody contacts at least one amino
acid residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118 (inclusive);
wherein the antibody contacts: at least two of the residues; preferably at least three of the
residues; more preferably at least four of the residues; more preferably at least five of the
residues; more preferably at least six of the residues; more preferably at least seven of the
residues; more preferably at least eight of the residues; more preferably at least nine of
the residues; more preferably at least ten of the residues; more preferably at least eleven
of the residues; more preferably at least twelve of the residues; more preferably at least
thirteen of the residues; or more preferably all of the residues; wherein the residues in
contact are within six (6) angstroms or less of the antibody, as determined by X-ray
crystallography; optionally, wherein said antibody blocks binding of human Tim-3 (SEQ
ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human
galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3 (SEQ ID NO:1) to
human CEACAM1 (SEQ ID: 39).
Also described is the use of a monoclonal antibody that binds an epitope of human
Tim-3 (SEQ ID NO:1) for the manufacture of a medicament for the treatment of cancer.
Also described is the use of a monoclonal antibody that binds human Tim-3 (SEQ ID
NO:1) for the manufacture of a medicament for the treatment of cancer, wherein said
binding blocks binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine,
but does not block binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ
ID: 39). Also described is the use of a monoclonal antibody that binds an epitope of
human Tim-3 (SEQ ID NO:1) for the manufacture of a medicament for the treatment of
cancer, wherein said binding blocks the binding of human Tim-3 (SEQ ID NO:1) to
human phosphatidylserine and human galectin-9 (SEQ ID: 40), but does not block
binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ ID: 39). Also
described is the use of a monoclonal antibody that binds an epitope of human Tim-3
(SEQ ID NO:1) for the manufacture of a medicament for the treatment of cancer in
simultaneous, separate, or sequential combination with one or more chemotherapeutic
agents.
Also described is the use of a monoclonal antibody that binds an epitope of human
Tim-3 (SEQ ID NO:1) for the manufacture of a medicament for the treatment of cancer,
wherein the cancer is melanoma, lung cancer, non-small cell lung cancer, head and neck
cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer,
prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft tissue sarcoma, or
liver cancer. Also described is the use of a monoclonal antibody that binds an epitope of
human Tim-3 (SEQ ID NO:1) for the manufacture of a medicament for the treatment of
cancer in simultaneous, separate, or sequential combination with ionizing radiation.
Also described is the use of a monoclonal antibody that binds human Tim-3 (SEQ ID
NO:1) for the manufacture of a medicament for the treatment of cancer, wherein said
binding blocks binding of human Tim-3 (SEQ ID NO:1) to human phosphatidylserine,
but does not block binding of human Tim-3 (SEQ ID NO:1) to human CEACAM1 (SEQ
ID: 39). Also described is the use of a monoclonal antibody that binds human Tim-3
(SEQ ID NO:1) for the manufacture of a medicament for the treatment of cancer, wherein
said binding blocks binding of human Tim-3 (SEQ ID NO:1) to human
phosphatidylserine and human Tim-3 (SEQ ID NO:1) to human galectin-9 (SEQ ID: 40),
but does not block binding of human Tim-3 (SEQ ID NO:1) (SEQ ID NO:1) to human
CEACAM1 (SEQ ID: 39). Also described is the use of an antibody that binds an epitope
on human Tim-3 (SEQ ID NO:1) for the manufacture of a medicament for the treatment
of cancer, wherein the antibody contacts residues 50, 55-65, 72, 107, 111, 113-120, and
122. Also described is the use of an antibody that binds an epitope on human Tim-3
(SEQ ID NO:1) for the manufacture of a medicament for the treatment of cancer, wherein
the antibody contacts residues 50, 55-65, 72, 107, 111, 113-120, and 122; wherein the
epitope is determined by X-ray crystallography and wherein the residues in contact are
within six (6) angstroms or less of the antibody; wherein said antibody blocks binding of
human Tim-3 (SEQ ID NO:1) to human phosphatidylserine and human Tim-3 (SEQ ID
NO:1)to human galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3
(SEQ ID NO:1)to human CEACAM1 (SEQ ID: 39).
Also described is the use of an antibody that binds an epitope on human Tim-3 (SEQ
ID NO:1) for the manufacture of a medicament for the treatment of cancer, wherein the
antibody contacts at least one residue of the following: 50, 55, 62-65 (inclusive), 72, 111,
and 113-118 (inclusive). Also described is the use of an antibody that binds an epitope on
human Tim-3 (SEQ ID NO:1) for the manufacture of a medicament for the treatment of
cancer, wherein the antibody contacts at least one residue of the following: 50, 55, 62-65
(inclusive), 72, 111, and 113-118 (inclusive), wherein the antibody contacts: at least two
of the residues; preferably at least three of the residues; more preferably at least four of
the residues; more preferably at least five of the residues; more preferably at least six of
the residues; more preferably at least seven of the residues; more preferably at least eight
of the residues; more preferably at least nine of the residues; more preferably at least ten
of the residues; more preferably at least eleven of the residues; more preferably at least
twelve of the residues; more preferably at least thirteen of the residues; or more
preferably all of the residues.
Also described is the use of an antibody that binds an epitope on human Tim-3 (SEQ
ID NO:1) for the manufacture of a medicament for the treatment of cancer, wherein the
antibody contacts at least one residue of the following: 50, 55, 62-65 (inclusive), 72, 111,
and 113-118 (inclusive); and wherein the antibody further contacts at least one residue of
the following: 56-61 (inclusive), 107, 119-120 (inclusive) , and 122. Also described is
the use of an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1) for the
manufacture of a medicament for the treatment of cancer, wherein the antibody contacts
at least one residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118
(inclusive), wherein the antibody contacts: at least two of the residues; preferably at least
three of the residues; more preferably at least four of the residues; more preferably at least
five of the residues; more preferably at least six of the residues; more preferably at least
seven of the residues; more preferably at least eight of the residues; more preferably at
least nine of the residues; more preferably at least ten of the residues; more preferably at
least eleven of the residues; more preferably at least twelve of the residues; more
preferably at least thirteen of the residues; or more preferably all of the residues; and
wherein the antibody further contacts at least one residue of the following: 56-61
(inclusive), 107, 119-120 (inclusive), and 122.
Also described is the use of an antibody that binds an epitope on human Tim-3 (SEQ
ID NO:1) for the manufacture of a medicament for the treatment of cancer, wherein the
antibody contacts at least one residue of the following: 50, 55, 62-65 (inclusive), 72, 111,
and 113-118 (inclusive); wherein the epitope is determined by X-ray crystallography and
wherein the residues in contact are within six (6) angstroms or less of the antibody;
wherein said antibody blocks binding of human Tim-3 (SEQ ID NO:1)to human
phosphatidylserine and human Tim-3 (SEQ ID NO:1)to human galectin-9 (SEQ ID: 40),
but does not block binding of human Tim-3 (SEQ ID NO:1)to human CEACAM1 (SEQ
ID: 39); and optionally, wherein the antibody further contacts at least one residue of the
following: 56-61 (inclusive), 107, 119-120 (inclusive) , and 122. Also described is the
use of an antibody that binds an epitope on human Tim-3 (SEQ ID NO:1) for the
manufacture of a medicament for the treatment of cancer, wherein the antibody contacts
at least one residue of the following: 50, 55, 62-65 (inclusive), 72, 111, and 113-118
(inclusive), wherein the antibody contacts: at least two of the residues; preferably at least
three of the residues; more preferably at least four of the residues; more preferably at least
five of the residues; more preferably at least six of the residues; more preferably at least
seven of the residues; more preferably at least eight of the residues; more preferably at
least nine of the residues; more preferably at least ten of the residues; more preferably at
least eleven of the residues; more preferably at least twelve of the residues; more
preferably at least thirteen of the residues; or more preferably all of the residues; wherein
the epitope is determined by X-ray crystallography and wherein the residues in contact
are within six (6) angstroms or less of the antibody; wherein said antibody blocks binding
of human Tim-3 (SEQ ID NO:1)to human phosphatidylserine and human Tim-3 (SEQ ID
NO:1)to human galectin-9 (SEQ ID: 40), but does not block binding of human Tim-3
(SEQ ID NO:1)to human CEACAM1 (SEQ ID: 39); and optionally, wherein the antibody
further contacts at least one residue of the following: 56-61 (inclusive), 107, 119-120
(inclusive), and 122.
A pharmaceutical composition for the treatment of cancer, comprising an antibody
that binds human Tim-3 (SEQ ID NO:1), the antibody comprising HCDR1, HCDR2,
HCDR3, LCDR1, LCDR2, and LCDR3 wherein: HCDR1 has the amino acid sequence of
SEQ ID: 2, HCDR2 has the amino acid sequence of SEQ ID NO: 3, HCDR3 has the
amino acid sequence of SEQ ID NO: 4, LCDR1 has the amino acid sequence of SEQ ID
NO:5, LCDR2 has the amino acid sequence of SEQ ID NO:6, and LCDR3 has the amino
acid sequence of SEQ ID NO:7; HCDR1 has the amino acid sequence of SEQ ID NO:14,
HCDR2 has the amino acid sequence of SEQ ID NO:15, HCDR3 has the amino acid
sequence of SEQ ID NO:16, LCDR1 has the amino acid sequence of SEQ ID NO:17,
LCDR2 has the amino acid sequence of SEQ ID NO:18, and LCDR3 has the amino acid
sequence of SEQ ID NO:19; or HCDR1 has the amino acid sequence of SEQ ID NO:26,
HCDR2 has the amino acid sequence of SEQ ID NO:27, HCDR3 has the amino acid
sequence of SEQ ID NO:28, LCDR1 has the amino acid sequence of SEQ ID NO:29,
LCDR2 has the amino acid sequence of SEQ ID NO:30, and LCDR3 has the amino acid
sequence of SEQ ID NO:31.
A pharmaceutical composition for the treatment of cancer, comprising an antibody
that binds human Tim-3 (SEQ ID NO:1), the antibody comprising a heavy chain variable
region (HCVR) and a light chain variable region (LCVR), wherein: the HCVR has the
amino acid sequence of SEQ ID NO: 8, and the LCVR has the amino acid sequence of
SEQ ID NO: 9; the HCVR has the amino acid sequence of SEQ ID NO: 20, and the
LCVR has the amino acid sequence of SEQ ID NO: 21; or the HCVR has the amino acid
sequence of SEQ ID NO: 32, and the LCVR has the amino acid sequence of SEQ ID NO:
A pharmaceutical composition for the treatment of cancer, comprising an antibody
that binds human Tim-3 (SEQ ID NO:1), the antibody comprising a heavy chain (HC)
and a light chain (LC), wherein: the HC has the amino acid sequence of SEQ ID NO: 10
and the LC has the amino acid sequence of SEQ ID NO: 11; the HC has the amino acid
sequence of SEQ ID NO: 22 and the LC has the amino acid sequence of SEQ ID NO: 23;
or the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the amino acid
sequence of SEQ ID NO: 35.
A pharmaceutical composition for the treatment of cancer, comprising an antibody
that binds human Tim-3 (SEQ ID NO:1), the antibody comprising a heavy chain (HC)
and a light chain (LC), wherein: the HC has the amino acid sequence of SEQ ID NO: 10
and the LC has the amino acid sequence of SEQ ID NO: 11; the HC has the amino acid
sequence of SEQ ID NO: 22 and the LC has the amino acid sequence of SEQ ID NO: 23;
or the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the amino acid
sequence of SEQ ID NO: 35; wherein the cancer is melanoma, lung cancer, head and
neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder
cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft tissue
sarcoma, or liver cancer.
A pharmaceutical composition for the treatment of cancer, comprising an antibody
that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts residues 50, 55-
65, 72, 107, 111, 113-120, and 122 of human Tim-3 (SEQ ID NO:1); wherein the
residues in contact are within six (6) angstroms or less of the antibody, as determined by
X-ray crystallography.
A pharmaceutical composition for the treatment of cancer, comprising an antibody
that binds human Tim-3 (SEQ ID NO:1), wherein the antibody contacts residues 50, 55-
65, 72, 107, 111, 113-120, and 122 of human Tim-3 (SEQ ID NO:1); wherein the
residues in contact are within six (6) angstroms or less of the antibody, as determined by
X-ray crystallography; wherein the cancer is melanoma, lung cancer, head and neck
cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer,
prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft tissue sarcoma, or
liver cancer.
In some embodiments, a method of evaluating the efficacy of an anti-human Tim-
3 (SEQ ID NO:1) antibody is provided, the method comprising (a) combining a murine T
cell hybridoma expressing human Tim-3 (SEQ ID NO:1), a murine antigen-presenting
cell, a peptide recognized by the murine T cell hybridoma, and an anti-human Tim-3
antibody, and (b) measuring murine cytokine production. In some embodiments, a
method of evaluating the efficacy of an anti-human Tim-3 antibody is provided, the
method comprising (a) combining a murine T cell hybridoma expressing human Tim-3
(SEQ ID NO:1), a murine antigen presenting cell, a peptide recognized by the murine T
cell hybridoma, and an anti-human Tim-3 antibody, and (b) measuring murine cytokine
production; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2,
HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ
ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26,
27, 28, 29, 30, and 31, respectively.
In some embodiments, a method of evaluating the efficacy of an anti-human Tim-
3 (SEQ ID NO:1) antibody is provided, the method comprising (a) combining a murine T
cell hybridoma expressing human Tim-3 (SEQ ID NO:1), a murine antigen-presenting
cell, a peptide recognized by the murine T cell hybridoma, and an anti-human Tim-3
antibody, and (b) measuring murine cytokine production; wherein the anti-human Tim-3
antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting
of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16,
17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively; wherein the
peptide recognized by the murine T cell hybridoma is ISQAVHAAHAEINEAGR (SEQ
ID NO: 38); wherein the murine cytokine is IL-2, interferon-gamma, TNF-alpha, or
combinations thereof.
In some embodiments, a method of evaluating the efficacy of an anti-human Tim-
3 antibody is provided, the method comprising (a) combining a murine T cell hybridoma
expressing human Tim-3 (SEQ ID NO:1), a murine antigen-presenting cell, a peptide
recognized by the murine T cell hybridoma,and an anti-human Tim-3 antibody, and (b)
measuring murine cytokine production; wherein the anti-human Tim-3 antibody
comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the
amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17,
18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively; wherein the peptide
recognized by the murine T cell hybridoma is ISQAVHAAHAEINEAGR (SEQ ID NO:
38); wherein the murine cytokine is IL-2, interferon-gamma, TNF-alpha, or combinations
thereof; wherein the murine cytokine production is measured by enzyme-linked
immunospot assay, enzyme-linked immunosorbent assay, or flow cytometry; and wherein
the murine antigen presenting cell is an A20 cell.
In some embodiments, a method of evaluating the efficacy of an anti-human Tim-
3 antibody is provided, the method comprising (a) combining a murine T cell hybridoma
expressing human Tim-3 (SEQ ID NO:1) and an anti-human Tim-3 antibody, and (b)
measuring the binding of the anti-human Tim-3 antibody to the murine T cell hybrioma
expressing Tim-3; wherein the anti-human Tim-3 antibody comprises HCDR1, HCDR2,
HCDR3, LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences of SEQ
ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16, 17, 18, and 19, respectively; or 26,
27, 28, 29, 30, and 31, respectively. In some embodiments, a method of evaluating the
efficacy of an anti-human Tim-3 antibody is provided, the method comprising (a)
combining a murine T cell hybridoma expressing human Tim-3 (SEQ ID NO:1) and an
anti-human Tim-3 antibody, and (b) measuring the binding of the anti-human Tim-3
antibody to the murine T cell hybrioma expressing Tim-3; wherein the anti-human Tim-3
antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 consisting
of the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively; 14, 15, 16,
17, 18, and 19, respectively; or 26, 27, 28, 29, 30, and 31, respectively; wherein the
binding of the anti-human Tim-3 antibody is measured by flow cytometry.
The murine antigen presenting preferably is syngeneic with the murine T cell
hybridoma prior to introducing the human Tim-3 gene into the murine T cell hybridoma.
The murine antigen presenting cells are murine cells that express the major
histocompatibility complex II gene(s); non-limiting examples of which include I-A .
Non-limiting examples of murine antigen presenting cells include B cells, dendritic cells,
and monocytes/macrophages. The murine antigen present cell can be a primary cell or a
cell line, a non-limiting example of which includes an A20 cell (ATCC® TIB-208™; a
murine B lymphocyte cell line derived from a BALB/cAnN mouse). Non-limiting
examples of murine T cell hybridomas include DO11.10 T cell hybridomas as described
by Shimonkevitz et al., Antigen Recognition by HRestricted T cells, Journal of
Immunology 133(4), pp. 2067-2074. In some embodiments, the murine cytokine
production is measured at the RNA level by methods including, but not limited to real-
time PCR, multiplex real time PCR, and PCR. In some embodiments, the murine
cytokines include other cytokines, non-limiting examples of which include IL-10, TNF-
beta/LT-alpha, IL-3, IL-4, IL-5, IL-6, IL-13, IL-17A, IL-17E, IL-17F, IL-17AF
heterodimer, IL-21, IL-22, IL-26, IL-31, GM-CSF, and MIP-3alpha.
An antibody of the present invention is an engineered, non-naturally occurring
polypeptide complex. A DNA molecule as described herein is a non-naturally occurring
DNA molecule that comprises a polynucleotide sequence encoding a polypeptide having
the amino acid sequence of one of the polypeptides in an antibody of the present
invention.
The antibody of the present invention is an IgG type antibody and has “heavy”
chains and “light” chains that are cross-linked via intra- and inter-chain disulfide bonds.
Each heavy chain is comprised of an N-terminal HCVR and a heavy chain constant
region (“HCCR”). Each light chain is comprised of a LCVR and a light chain constant
region (“LCCR”). When expressed in certain biological systems, antibodies having
native human Fc sequences are glycosylated in the Fc region. Typically, glycosylation
occurs in the Fc region of the antibody at a highly conserved N-glycosylation site. N-
glycans typically attach to asparagine. Antibodies may be glycosylated at other positions
as well.
Optionally, certain anti-Tim-3 antibodies described herein contain an Fc portion
that is derived from human IgG . IgG1 is well known to bind to the proteins of the Fc-
gamma receptor family (FcγR) as well as C1q. Interaction with these receptors can
induce antibody-dependent cell cytotoxicity (ADCC) and complement-dependent
cytotoxicity (CDC). Therefore, optionally, certain anti-Tim-3 antibodies described herein
are a fully human monoclonal antibody lacking Fc effector function (IgG1, Fc-null). To
achieve an Fc-null IgG1 antibody, selective mutagenesis of residues is necessary within
the CH2 region of its IgG1 Fc region. Amino acid substitutions L234A, L235E, and
G237A are introduced into IgG1 Fc to reduce binding to FcγRI, FcγRIIa, and FcγRIII,
and substitutions A330S and P331S are introduced to reduce C1q-mediated complement
fixation. To reduce the potential induction of an immune response when dosed in
humans, certain amino acids may require back-mutations to match antibody germline
sequences.
The HCVR and LCVR regions can be further subdivided into regions of hyper-
variability, termed complementarity determining regions (“CDRs”), interspersed with
regions that are more conserved, termed framework regions (“FR”). Each HCVR and
LCVR is composed of three CDRs and four FRs, arranged from amino-terminus to
carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
Herein, the three CDRs of the heavy chain are referred to as “HCDR1, HCDR2, and
HCDR3” and the three CDRs of the light chain are referred to as “LCDR1, LCDR2 and
LCDR3”. The CDRs contain most of the residues which form specific interactions with
the antigen. There are currently three systems of CDR assignments for antibodies that are
used for sequence delineation. The North CDR definition (North et al., “A New
Clustering of Antibody CDR Loop Conformations”, Journal of Molecular Biology, 406,
228-256 (2011)) is based on affinity propagation clustering with a large number of crystal
structures. For the purposes of the present invention, the North CDR definitions are used.
An isolated DNA encoding a HCVR region can be converted to a full-length
heavy chain gene by operably linking the HCVR-encoding DNA to another DNA
molecule encoding heavy chain constant regions. The sequences of human, as well as
other mammalian, heavy chain constant region genes are known in the art. DNA
fragments encompassing these regions can be obtained e.g., by standard PCR
amplification.
An isolated DNA encoding a LCVR region may be converted to a full-length light
chain gene by operably linking the LCVR-encoding DNA to another DNA molecule
encoding a light chain constant region. The sequences of human, as well as other
mammalian, light chain constant region genes are known in the art. DNA fragments
encompassing these regions can be obtained by standard PCR amplification. The light
chain constant region can be a human kappa or lambda constant region. Preferably for
antibodies of the present invention, the light chain constant region is a human kappa
constant region.
The polynucleotides as described herein will be expressed in a host cell after the
sequences have been operably linked to an expression control sequence. The expression
vectors are typically replicable in the host organisms either as episomes or as an integral
part of the host chromosomal DNA. Commonly, expression vectors will contain selection
markers, e.g., tetracycline, neomycin, and dihydrofolate reductase, to permit detection of
those cells transformed with the desired DNA sequences.
The antibody of the present invention may readily be produced in mammalian
cells, non-limiting examples of which includes CHO, NS0, HEK293 or COS cells. The
host cells are cultured using techniques well known in the art.
The vectors containing the polynucleotide sequences of interest (e.g., the
polynucleotides encoding the polypeptides of the antibody and expression control
sequences) can be transferred into the host cell by well-known methods, which vary
depending on the type of cellular host.
Various methods of protein purification may be employed and such methods are
known in the art and described, for example, in Deutscher, Methods in Enzymology 182:
83-89 (1990) and Scopes, Protein Purification: Principles and Practice, 3rd Edition,
Springer, NY (1994).
In other embodiments of the present invention, the antibody, or the nucleic acids
encoding the same, is provided in isolated form. As used herein, the term “isolated”
refers to a protein, peptide, or nucleic acid which is free or substantially free from any
other macromolecular species found in a cellular environment. “Substantially free” as
used herein means the protein, peptide, or nucleic acid of interest comprises more than
80% (on a molar basis) of the macromolecular species present, preferably more than 90%,
and more preferably more than 95%.
The antibody of the present invention, or pharmaceutical compositions comprising
the same, may be administered by parenteral routes (e.g., subcutaneous and intravenous).
An antibody of the present invention may be administered to a patient along with
pharmaceutically acceptable carriers, diluents, or excipients in single or multiple doses.
Pharmaceutical compositions of the present invention can be prepared by methods well
known in the art (e.g., Remington: The Science and Practice of Pharmacy, 22 ed.
(2012), A. Loyd et al., Pharmaceutical Press) and comprise an antibody, as disclosed
herein, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
Dosage regimens may be adjusted to provide the optimum desired response (e.g.,
a therapeutic effect). Treatment dosages may be titrated to optimize safety and efficacy.
Dosing schedules, for intravenous (i.v.) or non-intravenous administration, localized or
systemic, or combinations, thereof will typically range from a single bolus dosage or
continuous infusion to multiple administrations per day (e.g., every 4-6 hours), or as
indicated by the treating physician and the patient's condition.
The term "treating" (or "treat" or "treatment") refers to slowing, interrupting,
arresting, alleviating, stopping, reducing, or reversing the progression or severity of an
existing symptom, disorder, condition, or disease.
"Effective amount" means the amount of an antibody of the present invention or
pharmaceutical composition comprising an antibody of the present invention that will
elicit the biological or medical response of or desired therapeutic effect on a tissue,
system, animal, mammal or human that is being sought by the researcher, medical doctor,
or other clinician. An effective amount of the antibody may vary according to factors
such as the disease state, age, sex, and weight of the individual, and the ability of the
antibody to elicit a desired response in the individual. An effective amount is also one in
which any toxic or detrimental effect of the antibody is outweighed by the therapeutically
beneficial effects.
The term ‘comprising’ as used in this specification and claims means ‘consisting
at least in part of’. When interpreting statements in this specification and claims which
includes the ‘comprising’, other features besides the features prefaced by this term in each
statement can also be present. Related terms such as ‘comprise’ and ‘comprised’ are to
be interpreted in similar manner.
WINN Assay
The antibodies of the present invention can be tested for in vivo
immunomodulatory activity with the WINN assay. In the WINN assay, human NSCLC
tumor cells NCI-H292 and human immune cells (allogeneic) are mixed and co-implanted
into an immunodeficient mouse, and then followed by dosing with an immunomodulatory
agent. The ability of the immunomodulatory agent to inhibit or delay tumor formation or
support intra-tumroal persistence can be assessed as follows.
On day 0, NSG mice from Jackson Laboratories (7 weeks of age, female, in
groups of 8-10 mice) are implanted into the flank subcutaneously with either 2 x10 H292
cells, or a mixture of 2 x10 H292 cells and 1 x 10 human PBMCs in HBSS (0.2 ml total
volume). Starting on Day 0, mice are treated with an i.p. injection of control human IgG
at 10 mg/kg or Antibody A at 1 mg/kg or 10 mg/kg , one time per week for six weeks.
Animal well-being and behavior, including grooming and ambulation, are monitored at
least twice per week.
Tumor sections from the model can be analyzed for CD3-positive and CD8-
positive T cell persistence by measuring the presence of CD3-positive and CD8-positive
T cells by staining for CD3 and CD8 and analyzing with the Aperio ScanScope™. The
IHC Nuclear Image Analysis macro detects nuclear staining for a target chromogen for
the individual cells in those regions that are chosen by the user and quantifies their
intensities. Three to five annotations are made from viable tumor area and used in
adjusting the parameters until the algorithm results generate consistent cell identification.
The macro is then saved and the slides logged in for analysis. The % CD3-positive and
CD8-positive cells as a percent of the total number of cells are calculated by the Aperio
software.
In experiments performed essentially as described in this WINN assay, by IHC
analysis, mice co-implanted with NCI-H292 tumors and PBMCs and dosed with
Antibody A at 10 mg/kg results in a significant increase (30%) of human CD3-positive
CD8-positive intratumoral T cells as compared to mice co-implanted with NCI-H292
tumors and PBMCs and treated with the control IgG (6.5 %) (P = 0.03).
Established human tumor xenograft model in NSG mice humanized with primary human
T cells
The efficacy of the antibodies of the present invention can be tested in the NCI-
HCC827 human NSCLC (non-small cell lung cancer) xenograft model to assess the
ability to delay or destroy established tumors in the model. On day 0, 1x10 NCI-
HCC827 cells are implanted subcutaneously into the flank of NSG mice (7 weeks of age,
female, 8 mice per group). When tumors reach a volume of ~400 mm (~days 30-32), the
mice are infused (i.v.) with 2.5 x10 previously expanded human T cells. Previously
expanded human T cells are generated by isolating human T cells from whole blood and
expanding using Dynabeads® Human T-Activator CD3/CD28 for 10 days. Previously
expanded human T cells may be cryopreserved for later use. One day after T cell
infusion, mice are dosed at 10 mg/kg by weekly (4 total doses) i.p. injection with human
IgG or Antibody A. Animal well-being and behavior, including grooming and
ambulation are monitored at least twice per week.
Body weight and tumor volume are measured twice a week. Tumor volumes were
measured twice per week starting on day 4 post-cell implantation using electronic calipers
as described above. Tumor Volume (mm ) = π/6 * Length * Width . The antitumor
efficacy is expressed as T/C ratio in percent and calculated as summarized below: %T/C
is calculated by the formula 100 ΔT /ΔC if ΔT > 0 of the geometric mean values. ΔT =
mean tumor volume of the drug-treated group on the final day of the study – mean tumor
volume of the drug-treated group on initial day of dosing; ΔC = mean tumor volume of
the control group on the final day of the study – mean tumor volume of the control group
on initial day of dosing. Additionally, % Regression is calculated using the formula =
100 x ∆T/T if ΔT < 0. Animals with no measurable tumors are considered as
initial
Complete Responders (CR) and tumors with >50% regressions are Partial Responders
(PR).
In experiments performed essentially as described above, treatment with Antibody
A (anti-human Tim-3) significantly inhibits tumor growth in the humanized NSG mice,
compared to treatment with human IgG (Table 1). On day 76, treatment with Antibody A
results in a T/C = 2%. On day 110, Antibody A treatment results in a 3/8 CR.
Table 1: Tumor volume (mm ) in the NCI-HCC827 human NSCLC xenograft
model
Human IgG
Antibody A
Control
Day Mean SEM Mean SEM
21 152 13 164 85
28 289 24 309 160
332 28 358 186
34 388 32 403 209
36 414 34 505 262
40 706 59 628 326
43 752 62 733 380
47 858 71 763 396
50 932 77 747 387
55 982 81 807 418
57 1212 100 843 437
62 1324 110 553 287
65 1524 126 726 376
69 1492 124 602 312
72 1827 151 539 279
76 2030 168 375 196
79 375 196
83 414 218
85 331 175
90 192 103
93 235 128
97 173 95
100 118 65
103 125 69
106 120 67
110 131 73
Mixed Lymphocyte Reaction
The function of blocking Tim-3 signals by antibodies of the present invention may
be evaluated by measuring the release of cytokines during T cell activation. The levels of
certain cytokines, such as IFN- γ, are expected to increase if T cell activation is promoted
by treatment with antibodies of the present invention.
CD14 monocytes are isolated by negative selection from fresh human PBMC
obtained from a healthy donor (AllCells) using human monocyte isolation kit II
(Miltennyi Biotec). Human monocyte-derived dendritic cells are generated by culturing
the CD14 monocytes in complete RPMI-1640 medium in the presence of 62.5 ng/ml
hGM-CSF and 20 ng/ml hIL-4 for 7 days. CD4 T cells are purified from fresh human
PBMC of a different healthy donor (AllCells) by negative selection using the CD4 T cell
isolation kit (Miltenyi). The two types of cells are then mixed in individual wells of a 96-
well plate with 100 μl complete AIM-V medium containing 1x10 CD4 T cells and
2x10 immature DC per well. 100 μl complete AIM-V medium is added containing 100
nM human IgG1 or Antibody A in 6 replicates. After incubation for 3 days at 37 C at 5%
CO , supernatants are harvested and measured for human IFN-γ with an ELISA kit (R&D
Systems). An unpaired t-test is used to compare groups.
In experiments performed essentially as described above, the addition of Antibody
A significantly increases the secretion of IFN-γ as compared to the addition of control
human IgG1 (3,036 ± 367 vs. 1,644 ± 261 pg/mL of hIFN-γ; p=0.0384).
ELISA analysis: Antibody A binds to recombinant Tim-3
The ability for antibodies of the present invention to bind human Tim-3 can be
measured with an ELISA assay. For the Tim-3 binding assay, a 96-well plate (Nunc) is
coated with human TimFc (R&D Systems) overnight at 4 C. Wells are blocked for 2 h
with blocking buffer (PBS containing 3% bovine serum albumin). Wells are washed
three times with PBS containing 0.1% Tween-20. Antibody A or control IgG (100 μl) is
then added and incubated at room temperature for 1 h. After washing, the plate is
incubated with 100 μl of goat anti-human IgG F(ab’)2-HRP conjugate (Jackson Immuno
Research) at room temperature for 1 h. The plates are washed and then incubated with
100 μl of 3,3’, 5,5’-tetra-methylbenzidine. The absorbance at 450 nm is read on a
microplate reader. The half maximal effective concentration (EC50) is calculated using
GraphPad Prism 6 software.
In experiments performed essentially as described above, Antibody A binds
human Tim-3 with an EC50 of 2.07 x 10 M.
Flow cytometric analysis: Antibody A binds to cell surface Tim-3
The ability for antibodies of the present invention to bind to cell surface human
Tim-3 can be measured with a flow cytometric assay. Tim-3 DO11.10 cells, a human
Tim-3 expressing DO11.10 cell line, are used for this assay.
Tim-3 DO11.10 cells can be obtained as follows. Full-length Tim-3 gene can be
purchased from Origene Technologies, Inc. and cloned into a pLVX-IRES-Neo lentivirus
vector from Clonetech Laboraties, Inc. using PCR. Lenti-X™ system from Clonetech
Laboraties, Inc. is used to generate high titers of recombinant, replication-incompetent
virions. The virions are either used to infect the target cells immediately or are aliquoted
and frozen at -80 until use. The murine T cell hybridoma, DO11.10 cell line, can be
obtained from the National Jewish Health®. The DO11.10s are cultured and maintained
according to a protocol accompanying this cell line. On day 0, DO11.10 cells are counted
and spun down to remove culture media. Cell pellets are mixed with virions containing
the human TIM-3 gene or vector control and incubated at 37°C for 24 hours. Polybrene
is added when mixing cells and virions until a final concentration of 8 ug/ml is achieved.
After 24 hours, DO11.10 cells are pelleted again and resuspended in fresh culture media
and incubated at 37°C for 3 days. Next, the DO11.10 cells are pelleted every 3 days and
resuspended in selection media containing 1 mg/ml Geneticin® to select stably
transduced cells. Tim-3 expression is monitored by flow cytometry using antibodies
obtained from R&D Systems. After 2 to 3 weeks in selection media, the resulting Tim-3
expressing DO11.10 cells are sorted to establish a single cell clone.
DO11.10 and Tim-3 DO11.10 cells are added to a 96 well V-bottom plate at
1.x10 cells per well (100 μl/well) in staining buffer (DPBS containing 3% BSA). Cells
are Fc blocked on ice for 1 hour in staining buffer with 30 μg/mL human IgG. Antibody
A or control human IgG is labelled with A488 (Molecular Probes®) and 12 point
titrations (1:3 serial dilutions) of both antibodies are prepared in staining buffer with a
starting concentration of 66.7 nM. Labelled antibodies are added to the cells and
incubated for 1 hour at 4°C in the dark. Cells are washed two times with PBS by
spinning for 5 min at 1200 RPM and decanting the supernatant. Live/Dead cell dye 7-
AAD (1:1000 in PBS) is added to each well at 3 μl/well and cells are incubated for 15
min on ice. Cells are washed two times with PBS and resuspended in 100 μl DPBS
containing 0.5% BSA and analyzed on an Intellictye iQue. All stainings are done in
triplicate. Data are analyzed with FlowJo software to identify populations of live cells and
determine the median fluorescence intensity of each sample using the AF488 (FL1)
detection channel. The individual MFI (i.e. mean fluorescence intensity) values are
placed into GraphPad Prism software to generate concentration response curves from
which EC50 values are extrapolated.
In experiments performed essentially as described above, Antibody A binds to
cellular bound human Tim-3 on Tim-3 DO11.10 cells in a dose dependent manner with
an EC50 value of 0.09 nM.
Flow cytometric analysis: Antibody A blocks the interaction of phosphatidylserine
with human Tim-3 The ability for certain antibodies of the present invention to block
phosphatidylserine binding to Tim-3 can be measured by FACS analysis. For this
receptor-ligand blocking assay, 1x10 /ml of DO11.10 cells are treated with 12 μM
camptothecin (Sigma®) for 3 hours at 37 °C to induce apoptosis. FITC-Annexin V
(Becton Dickinson®) is used as a positive control to detect the existence of
phosphatidylserine. Biotinylated hTIMFc binds strongly to camptothecin-treated cells
but does not bind to non-treated cells. Camptothecin-treated cells are washed with cold
PBS and resuspended in binding buffer (Becton Dicknson®) at 1x10 cells/ml. Fc
receptors are blocked by adding 50 μg/ml mouse IgG and rat IgG to the cells and
incubating at room temperature for 30 min. 6 point titrations (1:3 serial dilutions) of
Antibody A are prepared in binding buffer with a starting concentration of 90 nM and
added to 1 ml of cells and cells are then incubated for 60 min at room temperature.
hTIMFc Biotin is then added at 0.05 μg/well to the appropriate samples in a 200 μl
volume and incubated for 30 min at room temperature. Cells are then washed twice with
binding buffer by centrifugation at 1200 RPM for 5 min. 2.4 μl/well of a streptavidin-
FITC (Biolegend®) containing solution (1:10 dilution in DPBS) and 5 μl/well of
propidium iodide are added to each well and incubated for 30 min at room temperature in
the dark. Cells are washed twice with binding buffer and resuspended in 100 μl of PBS.
Samples are read on the IntelliCyt iQue Flow Cytometer and Data were analyzed with
FlowJo software. The individual MFI (i.e. mean fluorescence intensity) values are placed
into GraphPad Prism software to generate concentration response curves from which
IC50 values are extrapolated.
In experiments performed essentially as described above, Antibody A blocks the
interaction of human Tim-3 with phosphatidylserine in a dose-dependent manner with an
IC50 value of 0.32 nM and as further illustrated in Table 2.
Table 2
Untreated Camptothecin-treated DO11.10+ hTIMFc Biotin
DO11.10
+ hTIM-
3-Fc
Biotin
Antibo 0 90 30 10 3.3 1.1 0.37 0
dy A
(nM)
MFI 1747 1815 19655 32574 52885 96566 197146 214044
Galectin-9 Blocking Assay: Antibody A blocks the interaction of human galectin-9
with human Tim-3
The ability for antibodies of the present invention to block human galectin-9
binding to human Tim-3 can be measured as follows. For this receptor-ligand blocking
assay, a 96-well streptavidin-coated MSD plate (Meso Scale Diagnostics) is blocked for 2
hours with 150 μl blocking buffer (PBST containing 5% bovine serum albumin). Wells
are washed three times with 200 μl PBS containing 0.2% Tween-20. Recombinant
human galectin-9 (R&D Systems) is biotinylated using EZ-Link™ biotin (Thermo
Scientific™) and then 25 μl of 0.21 μg/ml of the human recombinant galectinbiotin is
then added and incubated at room temperature for 2 hours. Plates are washed three times
with PBS containing 0.2% Tween-20. Human TimFc protein (R&D Systems) is
ruthinylated using sulfo-tag NHS-ester reagent (Meso Scale Discovery®) and a small
aliquot is stored at -80 until use. Antibodies are serially diluted (starting at 13.5 μg/ml)
and 50 μl of each antibody combined with 50 μl of diluted hTimFc-ruth at 0.05 μg/ml
and incubated for 1 hour at room temperature. 50 μl of each combination is then added to
the plate and incubated for 1.5 hours at room temperature. Plates are washed three times
with PBS containing 0.2% Tween-20. 150 μl of 1X read buffer (Meso Scale Diagnostics)
is then added to each well of the plate and the plate is read on a Sector Imager 2400
(Meso Scale Diagnostics).
In experiments performed essentially as described above, Antibody A blocks the
interaction of human Tim-3 with human galectin-9 with an IC50 value of 5.6 nM as
compared to control a polyclonal anti-human Tim-3 antibody (R&D Systems) with an
IC50 value of 7.8 nM. However, The polyclonal anti-human Tim-3 antibody can block
up to 100% human Tim-3’s interactions with human galectin-9 while Antibody A only
achieve partial blockage in this assay.
CEACAM-1 Blocking Assay: Antibody A does not block the interaction of human
CEACAM1 with human Tim-3
The ability for antibodies of the present invention to block human CEACAM1
binding to human Tim-3 can be measured as follows. For this receptor-ligand blocking
assay, a 96-well Immulon 4HBX plate (Thermo Scientific) is coated with 100 μl/well of
1ug/ml human TimFc at 4 °C. The plate is washed three times with PBS containing
0.2% Tween-20 and blocked with 200 μl/well of PBS with 3% BSA for 1 hour at room
temperature. Blocking buffer is then removed and 50 μl of titrated Abs (including
polyclonal anti-human Tim-3, R&D Systems, Antibody A, and control human IgG),
starting at 600 nM are added to the plate and incubated for 1 hour at room temperature.
50 μl of 20 μg/ml of CEACAM1 (BIOTANG) is then added directly to the wells and
incubated for 1 hour at room temperature (final concentration of antibody is 300 nM and
of CEACAM1 is 10 μg/ml). The plate is washed three times with PBS containing 0.2%
Tween-20 and 100 μl of 0.2 μg/ml of biotinylated human CEACAM1 antibody (R&D
Systems) is added and then incubated for 1 hour at room temperature. The plate is
washed three times with PBS containing 0.2% Tween-20 and then 100 μl of streptavidin
peroxidase (Jackson ImmunoResearch Laboratories) is added and then incubated for 1
hour at room temperature. The plate is washed six times with PBS containing 0.2%
Tween-20 and developed using 100 μl/well of a 1:1 TMB substrate solution A and B
(KPL) for 10 min at room temperature. The reaction is then stopped with 100 μl/well of
0.1N H SO and the plate is read on a SpectraMax® plate reader at 450 nm.
In experiments performed essentially as described above, Antibody A does not
significantly block the binding of CEACAM1 to human Tim-3, as illustrated in Table 3
below.
Table 3
Concentrati
on of
0.015 0.046 0.137 0.41 1.24 3.71 11.1 33.3 100 300
Antibody
(nM)
Human
IgG Control 2.05 2.02 2.13 2.03 2.04 2.03 2.05 2.07 2.12 2.08
(O.D.)
Polyclonal
Anti-Tim-3 1.96 1.88 1.89 1.88 1.85 1.80 1.51 1.16 0.99 0.99
(O.D.)
Antibody A
1.87 1.88 1.87 1.82 1.80 1.78 1.79 1.79 1.73 1.74
(O.D.)
Epitope
A Fab for Antibody A is generated by by enzymatically clipping Antibody A with
immobilized (agarose resin) papain (ThermoFisher Scientific) followed by a standard
ProA column (GE Healthcare Life Sciences) purification to pull out the free, soluble Fc
and the unclipped IgG. Flow through containing the Fab is collected to concentrate and
buffer exchange. The hTimIgV-FLAG is purified from the 293HEK supernatant with
a standard anti-FLAG resin (Sigma-Aldrich) protocol. The hTimIgV domain
represents amino acid residues S22 to K130 of human Tim-3 (SEQ ID:1). Flow through
is rerun in the resin column multiple times. After each run, SDS-PAGE (NuPAGE Novex
4-12% Bis-Tris Gels; Invitrogen) and HPLC (TSKgel G3000 SW XL (Dimensions:
7.8mm, ID 30 CM, 5 μM; TOSHO BioSCIENCE) is utilized to determine quality of the
hTimFLAG protein. Proteins of the best rounds are combined together to generate the
final batch.
hTimIgV-FLAG, at 2.17 mg/mL in TBS buffer pH 7.2, and Antibody A-Fab, at
6.79 mg/mL, are combined in a 1:1 molar ratio and the complex is isolated via size
exclusion chromatography with a final concentration of 6.9 mg/mL in 20 mM hepes pH
7.4 and 150 mM sodium chloride. The Timanti-Tim-3 complex is screened in five
Qiagen grid screens at both 8°C and 21°C using the sitting drop vapor diffusion method.
Drops are set up using an Art Robbins Phoenix liquid handling robot which dispenses 0.3
μL crystallization solution on top of 0.3 μL protein. 100-200 μm intergrown prisms are
obtained at 21°C in 20% PEG 3350 and 0.2 M lithium chloride. Crystals are harvested
and cryoprotected in a solution made of the crystallization condition supplemented with
% ethylene glycol prior to flash freezing in liquid nitrogen. A dataset is collected at
Argonne National Laboratory diffracting to 2.2 Å in space group P21 with cell parameters
a = 74.62 Å, b = 57.85 Å, and c = 74.71 Å.
The structure of the Antibody A-Fab in complex with human Tim-3 is determined
by Molecular Replacement using the program Phaser. High resolution and publicly
available Fab structures and the published structure of murine Tim-3 can be used as
Molecular Replacement models. The structure is refined using the program Refmac and
the model rebuilt using the program COOT. Final refinement R-factors are
Rwork=20.2%, Rfree=23.4%. There are no Ramachandran violators, and 96.4% of the
residues are in the favored region of the Ramachandran plot. There is density indicating
glycosylation at Asn99 of Tim-3 (SEQ ID NO:1).
Biacore T200 is utilized to determine the binding kinetics of hTimIgV-FLAG
to the captured AntibodyA-Fab. In HBS-EP as a running buffer, 1:1 binding of this
complex at 25°C has a k of 3.62E+05 1/Ms, k of 2.86E-03 1/s, and a K of 7.92E-09
on off D
M.
In experiments performed essentially as described in this assay, Antibody A-
Fab/hTim-3 complex is resolved and the epitope/paratope is illustrated in Table 4 below.
Table 4 below lists the residues on Antibody A-Fab that are within 6Å of the listed
residues on hTim-3 (SEQ ID NO:1). The heavy chain of the Antibody A-Fab has 62
contacts (cutoff 6 Å) with hTim-3 while the light chain has 34 contacts (cutoff 6 Å).
Table 4
Tim-3 Antibody A Antibody A
(Epitope) Heavy Chain Light Chain
(Paratope) (Paratope)
P50 S54 --
K55 -- Y32
G56 -- Y32
A57 -- Y30, Y32, N92
C58 -- Y32, A91, N92,
P59 Y99, T102 Y32, A91, N92,
V60 Y59, Y99, T102 Y32, Q89,
Q90,A91, N92,
S93, F94, P95, P96
F61 Y33, S35, W47, A91, F94, P96
A50, Y59, Y99,
A100, T102, F104
E62 S31, Y33, Y59, --
Y99, R101
C63 Y99, R101, T102 Y32
G64 T102 Y32
N65 T102 N31, Y32, A50
E72 S54 --
I107 -- T30
R111 Y33, Y59 --
Q113 Y33, S52, G53, --
S54, G55, G56,
S57,Y59
I114 G56, S57 --
P115 G56, S57 --
G116 G56, S57, T58, --
I117 G56, S57, T58, --
Y59, Y60, K65
M118 S57, T58, Y59, F94
Y60, A61, D62,
N119 T58, Y59 --
D120 Y33, S57, Y59 --
K122 -- N92, F94
Competition assay
A competition assay can be performed to determine whether Antibody B and
Antibody C compete with Antibody A for binding to human Tim-3. An Octet® Red384
instrument and AR2G (Amine Reactive Second Generation) Biosensors from ForteBIO
can be used for this assay. Biosensors are rehydrated in H2O for a minimum of 30
minutes before being activated with 20 mM 1-Ethyl(3-dimethylaminopropyl)-
carbodiimide (EDC) and 10 mM N-hydroxysuccinimide (NHS) for 300 seconds.
Antibodies at 2 ug/ml in 10 mM sodium acetate buffer, pH 4.5 are coupled to the sensor
through free amines for 500 sec and the coupling reaction is quenched with 1M
ethanolamine for 400 seconds. Sensors are dipped in kinase buffer (obtained from the
AR2G reagent kit (ForteBIO)) for baseline measurement for 300 seconds. Sensors are
then dipped into a 100 nM human TimIgV-Fc single arm antigen (SAG in kinase
buffer for 500 sec to enable the binding of the antigen to amine coupled antibodies on the
sensor. Next, sensors are dipped into 100 nM of test antibodies in kinase buffer for 300
seconds to test for competition. Sensograms are visualized using the ForteBio Data
Analysis 8.0 software. Each trace is visually compared to its respective “self-self”
control. If additional binding is observed when sensors are dipped into the test
antibodies, the test antibody is considered not to compete with the antibody coupled to the
sensor for binding to the antigen. If no additional binding is observed, the test antibody is
considered to be blocked by or to compete with the fixed antibody for binding to the
antigen.
In experiments performed essentially as described here, no additional binding is
observed for either Antibody B or Antibody C when Antibody A is coupled to the sensor,
and vice versa. These data demonstrate that Antibody B and Antibody C compete with
Antibody A for binding to human Tim-3.
hTIM-3 DO11.10 cell based assay using Antibody A, Antibody B, and Antibody C
The ability for antibodies of the present invention to bind to cellular bound human
Tim-3 and promote T cell activation can be measured using a human Tim-3 expressing
DO11.10 cell line and measuring for IL-2 production. For the huma Tim-3 DO11.10 cell
based assay, 2x10 cells/well (in 50 microliters) of either DO11.10 or DO11.10 cells
expressing human Tim-3 are plated with 2x10 cells/well of A20 cells (in 50 microliters)
in a 96 well U bottom tissue culture plate (Greiner CELLSTAR®) with RPMI 1640
media (Gibco®). 50 μl of OVA peptide (323-339) (Sigma-Aldrich®) is added to achieve
a final concentration of 0.2 uM (diluted in media). Antibody A, Antibody B, Antibody C,
or control human IgG is diluted into RPMI 1640 media starting from 200 nM with a
dilution factor of 3 to give concentrations of 0.09, 0.27, 0.82, 2.47, 7.41, 22.2, 66.7 and
200 nM. 50 μl of the diluted Antibody A, Antibody B, Antibody C, or control human IgG
is added to each well. RPMI 1640 media is then added as needed to achieve a final
volume of 200 μl/well. Supernatants are collected 18-22 hours after stimulation and IL-2
levels in the supernatants are measured by ELISA (R&D Systems®). The EC50 is
calculated with GraphPad software.
In experiments performed essentially as described above, Antibody A, Antibody
B, and Antibody C enhance OVA-specific T cell activation in a dose-dependent manner
with the EC50 values shown in Table 5.
Table 5
Antibody A Antibody B Antibody C
EC50 (nM) 3.707 6.079 3.352
Kinetics/Affinity study for Antibody A, Antibody B, and Antibody C
A Biacore T100 instrument can be used to measure the kinetics of human Tim
IgV-Fc single arm antigen (SAG) binding to captured Antibody A, Antibody B, or
Antibody C. Human Fab Binder surfaces are prepared by amine-coupling Human Fab
Binder (GE Healthcare) to a Biacore CM5 sensor chip surface. Test antibodies are
captured by the chip using HBS-EP buffer (GE Healthcare) as the running buffer. Tim-3
SAG is diluted into running buffer starting at 30 nM with a dilution factor of 3 to give
concentrations of 0.04, 0.12, 0.37, 1.11, 3.33, 10 and 30 nM. Diluted Tim-3 SAG analyte
or buffer is injected at 30 µl/min for 180 seconds and the complex dissociation is
monitored for 1200 seconds. The binding surface is regenerated with injection of 10mM
Glycine-HCl pH 2.1 at 30 µl/min, 30 seconds of two injections for five lower
concentrations, and two injections at 60 seconds for two higher concentrations between
each analyte binding cycle. Experimental data for a given antigen/Ab interaction are fit
using a 1:1 Langmuir with mass transport Model.
In experiments performed essentially as described above, Antibody A, Antibody
B, and Antibody C bind to human Tim-3 with the kinetics and affinity constants
illustrated in Table 6.
Table 6
Antibody K (1/Ms) K (1/s) K (M) R
on off D max
Antibody 6.75E+05 1.06E-04 1.58E-10 17.36 0.115
Antibody 7.97E+05 1.38E-04 1.73E-10 32.56 0.404
Antibody 2.33E+06 9.27E-04 3.98E-10 17.09 0.319
Antibody generation, expression, and purification
The antibodies of the present invention may be generated by known methods
including use of, but not limited to, phage display, transgenic animals, and humanization.
Additionally, the antibodies derived as described above may be further screened using the
assays described herein.
The polypeptides of the variable regions of the heavy chain and light chain, the
complete heavy chain and light chain amino acid sequences of Antibodies A through C,
and the nucleotide sequences encoding the same, are listed in the section entitled “Amino
Acid and Nucleotide Sequences.” In addition, the SEQ ID NOs for the light chain, heavy
chain, light chain variable region, and heavy chain variable region of Antibodies A
through C are shown in Table 7.
The antibodies of the present invention, including, but not limited to, Antibodies
A through C can be made and purified essentially as follows. An appropriate host cell,
such as HEK 293 or CHO, can be either transiently or stably transfected with an
expression system for secreting antibodies using an optimal predetermined HC:LC vector
ratio or a single vector system encoding both HC and LC. Clarified media, into which the
antibody has been secreted, may be purified using any of many commonly-used
techniques. For example, the medium may be conveniently applied to a MabSelect
column (GE Healthcare), or KappaSelect column (GE Healthcare) for Fab fragment, that
has been equilibrated with a compatible buffer, such as phosphate buffered saline (pH
7.4). The column may be washed to remove nonspecific binding components. The
bound antibody may be eluted, for example, by pH gradient (such as 20 mM Tris buffer
pH 7 to 10 mM sodium citrate buffer pH 3.0, or phosphate buffered saline pH 7.4 to 100
mM glycine buffer pH 3.0). Antibody fractions may be detected, such as by UV
absorbance or SDS-PAGE, and then may be pooled. Further purification is optional,
depending on the intended use. The antibody may be concentrated and/or sterile filtered
using common techniques. Soluble aggregate and multimers may be effectively removed
by common techniques, including size exclusion, hydrophobic interaction, ion exchange,
multimodal, or hydroxyapatite chromatography. The purity of the antibody after these
chromatography steps is greater than 95%. The product may be immediately frozen at -
70°C or may be lyophilized.
Table 7
Corresponding SEQ ID Antibody Antibody Antibody
A B C
HCDR1 2 14 26
HCDR2 3 15 27
HCDR3 4 16 28
LCDR1 5 17 29
LCDR2 6 18 30
LCDR3 7 19 31
HCVR 8 20 32
LCVR 9 21 33
Heavy chain 10 22 34
Light chain 11 23 35
DNA Heavy Chain 12 24 36
DNA Light Chain 13 25 37
Amino Acid and Nucleotide Sequences
SEQ ID NO: 1 (human Tim-3)
MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWG
KGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIENVTLADSGIY
CCRIQIPGIMNDEKFNLKLVIK
SEQ ID NO: 2 (HCDR1 of Antibody A)
AASGFTFSSYYMS
SEQ ID NO: 3 (HCDR2 of Antibody A)
AISGSGGSTYYADSVKG
SEQ ID NO: 4 (HCDR3 of Antibody A)
ARYARTAFDL
SEQ ID NO: 5 (LCDR1 of Antibody A)
QASQDIYNYLN
SEQ ID NO: 6 (LCDR2 of Antibody A)
YAASSLQS
SEQ ID NO: 7 (LCDR3 of Antibody A)
QQANSFPPT
SEQ ID NO: 8 (HCVR of Antibody A)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSAISGS
GGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYARTAFDLW
GQGTLVTVSS
SEQ ID NO: 9 (LCVR of Antibody A)
DIVMTQSPSSLSASVGDGVTITCQASQDIYNYLNWYQQKPGKAPKLLIYAASSLQ
SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGQGTKLEIK
SEQ ID NO: 10 (HC of Antibody A)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSAISGS
GGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYARTAFDLW
GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPK
SCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE
SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
TQKSLSLSPGK
SEQ ID NO: 11 (LC of Antibody A)
DIVMTQSPSSLSASVGDGVTITCQASQDIYNYLNWYQQKPGKAPKLLIYAASSLQ
SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGQGTKLEIKRTVAA
PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO: 12 (DNA of HC of Antibody A)
GAGGTGCAGCTGTTGGAGTCTGGCGGAGGGCTGGTGCAGCCGGGAGGCAGCC
TCAGGCTGAGCTGCGCTGCGAGCGGGTTTACTTTCTCGTCGTACTATATGTCG
TGGGTGAGACAAGCACCAGGTAAAGGACTTGAGTGGGTGTCCGCTATCTCAG
GCAGCGGAGGATCCACCTACTACGCGGATTCAGTCAAGGGAAGATTCACTAT
CTCGCGCGACAATTCCAAGAACACCCTGTACCTCCAGATGAACTCGCTGCGG
GCAGAAGATACGGCCGTGTACTACTGTGCCCGCTACGCCCGGACCGCCTTCG
ACTTGTGGGGTCAGGGAACCCTGGTCACTGTCTCCTCAGCTAGCACCAAGGG
CCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAG
CGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTC
GTGGAACTCAGGCGCACTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTA
CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAG
CTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACC
AAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCC
CACCGTGCCCAGCACCTGAAGCCGAGGGGGCACCGTCAGTCTTCCTCTTCCCC
CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCG
TGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTATGT
GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAAGACTGG
40 CTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCATCCT
CCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAAGTCAGCCTG
ACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGA
GCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTC
CGACGGCTCCTTCTTCCTCTATTCCAAGCTCACCGTGGACAAGAGCAGGTGGC
AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA
CTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGCAAA
SEQ ID NO: 13 (DNA of LC of Antibody A)
GACATCGTGATGACTCAAAGCCCTTCAAGCCTCTCGGCGTCAGTCGGTGATGG
CGTGACCATTACCTGTCAAGCATCCCAAGACATCTACAACTACTTGAATTGGT
ACCAGCAGAAGCCAGGGAAAGCCCCGAAGCTGCTGATCTACGCCGCCTCCTC
ACTTCAGAGCGGAGTGCCATCCCGCTTTTCCGGATCGGGGAGCGGAACGGAT
TTCACTCTGACCATCTCGTCGCTGCAACCGGAGGACTTCGCGACTTACTATTG
CCAGCAGGCTAACTCGTTCCCGCCCACTTTCGGACAGGGCACCAAGCTCGAA
ATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA
GCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAA
CTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC
AGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC
GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCA
ACAGGGGAGAGTGT
SEQ ID NO: 14 (HCDR1 of Antibody B)
AASGFSFSSFYFS
SEQ ID NO: 15 (HCDR2 of Antibody B)
AISGNGRSTYYADSVKG
SEQ ID NO: 16 (HCDR3 of Antibody B)
ARYYNTGFDL
SEQ ID NO: 17 (LCDR1 of Antibody B)
QASEAIYGYLN
SEQ ID NO: 18 (LCDR2 of Antibody B)
YAASSLPI
SEQ ID NO: 19 (LCDR3 of Antibody B)
QQAYGFPPT
SEQ ID NO: 20 (HCVR of Antibody B)
EVQLLESGGGLVQPGGSLRLSCAASGFSFSSFYFSWVRQAPGKGLEWVSAISGNG
RSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYYNTGFDLWG
QGTLVTVSS
SEQ ID NO: 21 (LCVR of Antibody B)
DIVMTQSPSSLSASVGDGVTITCQASEAIYGYLNWYQQKPGKAPKLLIYAASSLPI
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAYGFPPTFGQGTKLEIK
SEQ ID NO: 2 2 (HC of Antibody B)
EVQLLESGGGLVQPGGSLRLSCAASGFSFSSFYFSWVRQAPGKGLEWVSAISGNG
RSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYYNTGFDLWG
QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL
TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS
CDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
LPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
TQKSLSLSPGK
SEQ ID NO: 2 3 (LC of Antibody B)
DIVMTQSPSSLSASVGDGVTITCQASEAIYGYLNWYQQKPGKAPKLLIYAASSLPI
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAYGFPPTFGQGTKLEIKRTVAA
PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO: 2 4 (DNA of HC of Antibody B)
GAGGTGCAGCTGCTGGAATCCGGAGGAGGACTGGTCCAGCCAGGAGGCAGC
CTGCGACTGTCCTGTGCCGCTTCTGGCTTCAGTTTTTCTAGTTTCTATTTTTCCT
GGGTGCGGCAGGCTCCCGGCAAGGGACTGGAGTGGGTCTCTGCAATCAGCGG
CAACGGGCGTTCTACATACTATGCCGACAGTGTGAAAGGCAGGTTTACCATT
AGCCGGGACAACTCAAAGAATACACTGTACCTGCAGATGAACTCTCTGCGAG
CCGAAGACACTGCCGTGTACTATTGCGCCCGGTATTATAATACCGGGTTCGAT
CTGTGGGGACAGGGCACCCTGGTGACAGTCTCATCTGCTAGCACCAAGGGCC
CATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCG
GCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTG
GAACTCAGGCGCACTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG
TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTT
GGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAG
GTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCAC
CGTGCCCAGCACCTGAAGCCGAGGGGGCACCGTCAGTCTTCCTCTTCCCCCCA
AAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGG
TGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTATGTGGA
CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAA
CAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAAGACTGGCTGA
ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCATCCTCCAT
CGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTA
CACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAAGTCAGCCTGACC
TGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA
ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGA
CGGCTCCTTCTTCCTCTATTCCAAGCTCACCGTGGACAAGAGCAGGTGGCAGC
AGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC
ACGCAGAAGAGCCTCTCCCTGTCTCCGGGCAAA
SEQ ID NO: 2 5 (DNA of LC of Antibody B)
GACATCGTGATGACCCAGTCCCCAAGCTCCCTGAGCGCCAGCGTGGGAGACG
GCGTCACCATCACATGCCAGGCCTCTGAAGCCATCTACGGCTATCTGAATTGG
TACCAGCAGAAGCCAGGGAAAGCCCCCAAGCTGCTGATCTATGCCGCTTCTA
GTCTGCCGATCGGAGTGCCCAGTAGGTTCTCTGGGAGTGGATCAGGCACAGA
CTTTACTCTGACCATTTCAAGCCTGCAGCCTGAGGATTTCGCTACTTACTATTG
CCAGCAGGCTTATGGGTTCCCCCCTACATTTGGGCAGGGAACTAAACTGGAG
ATCAAGCGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA
GCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAA
CTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC
AGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC
GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCA
ACAGGGGAGAGTGT
SEQ ID NO: 26 (HCDR1 of Antibody C)
AASGFTFSSYYMS
SEQ ID NO: 27 (HCDR2 of Antibody C)
AISGNGKSTYYADSVKG
40 SEQ ID NO: 28 (HCDR3 of Antibody C)
ARYYNTGFDL
SEQ ID NO: 29 (LCDR1 of Antibody C)
QASQDIYNYLN
SEQ ID NO: 30 (LCDR2 of Antibody C)
YYASSIVS
SEQ ID NO: 31 (LCDR3 of Antibody C)
QQANSFPPT
SEQ ID NO: 32 (HCVR of Antibody C)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSAISGN
GKSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYYNTGFDLW
GQGTLVTVSS
SEQ ID NO: 33 (LCVR of Antibody C)
DIVMTQSPSSLSASVGDGVTITCQASQDIYNYLNWYQQKPGKAPKLLIYYASSIVS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGQGTKLEIK
SEQ ID NO: 34 (HC of Antibody C)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSAISGN
GKSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYYNTGFDLW
GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPK
SCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE
SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
TQKSLSLSPGK
SEQ ID NO: 35 (LC of Antibody C)
DIVMTQSPSSLSASVGDGVTITCQASQDIYNYLNWYQQKPGKAPKLLIYYASSIVS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGQGTKLEIKRTVAAP
SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO: 36 (DNA of HC of Antibody C)
GAGGTGCAGCTGCTGGAATCCGGAGGAGGACTGGTCCAGCCAGGAGGCAGC
CTGCGACTGTCCTGTGCCGCTTCTGGCTTCACTTTTTCTAGTTACTATATGTCC
TGGGTGCGGCAGGCTCCCGGCAAGGGACTGGAGTGGGTCTCTGCAATCAGCG
GCAACGGAAAATCTACATACTATGCCGACAGTGTGAAAGGCAGGTTTACCAT
TAGCCGGGACAACTCAAAGAATACACTGTACCTGCAGATGAACTCTCTGCGA
GCCGAAGACACTGCCGTGTACTATTGCGCCCGGTATTATAATACGGGGTTCGA
TCTGTGGGGACAGGGCACCCTGGTGACAGTCTCATCTGCTAGCACCAAGGGC
CCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGC
GGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGT
GGAACTCAGGCGCACTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACA
GTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCT
TGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAA
GGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCCGAGGGGGCACCGTCAGTCTTCCTCTTCCCCCC
AAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTG
GTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTATGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACA
ACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAAGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCATCCTCCA
TCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTA
CACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAAGTCAGCCTGACC
TGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA
ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGA
CGGCTCCTTCTTCCTCTATTCCAAGCTCACCGTGGACAAGAGCAGGTGGCAGC
AGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC
ACGCAGAAGAGCCTCTCCCTGTCTCCGGGCAAA
SEQ ID NO: 37 (DNA of LC of Antibody C)
GACATCGTGATGACCCAGTCCCCAAGCTCCCTGAGCGCCAGCGTGGGAGACG
GCGTCACCATCACATGCCAGGCCTCTCAGGATATCTACAACTATCTGAATTGG
TACCAGCAGAAGCCAGGGAAAGCCCCCAAGCTGCTGATCTATTACGCTTCTA
GTATTGTCTCTGGAGTGCCCAGTAGGTTCTCTGGGAGTGGATCAGGCACAGAC
TTTACTCTGACCATTTCAAGCCTGCAGCCTGAGGATTTCGCTACTTACTATTGC
CAGCAGGCAAACAGCTTCCCCCCTACATTTGGGCAGGGAACTAAACTGGAGA
TCAAGCGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAG
CAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCC
CAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAAC
TCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCA
40 GCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGC
CTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAAC
AGGGGAGAGTGT
SEQ ID NO: 38 (Ovalbumin peptide 323-339)
ISQAVHAAHAEINEAGR
SEQ ID NO: 39 (Human CEACAM1)
MGHLSAPLHRVRVPWQGLLLTASLLTFWNPPTTAQLTTESMPFNVAEGKEVLLL
VHNLPQQLFGYSWYKGERVDGNRQIVGYAIGTQQATPGPANSGRETIYPNASLLI
QNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVA
FTCEPETQDTTYLWWINNQSLPVSPRLQLSNGNRTLTLLSVTRNDTGPYECEIQNP
VSANRSDPVTLNVTYGPDTPTISPSDTYYRPGANLSLSCYAASNPPAQYSWLINGT
FQQSTQELFIPNITVNNSGSYTCHANNSVTGCNRTTVKTIIVTELSPVVAKPQIKAS
KTTVTGDKDSVNLTCSTNDTGISIRWFFKNQSLPSSERMKLSQGNTTLSINPVKRE
DAGTYWCEVFNPISKNQSDPIMLNVNYNALPQENGLSPGAIAGIVIGVVALVALI
AVALACFLHFGKTGRASDQRDLTEHKPSVSNHTQDHSNDPPNKMNEVTYSTLNF
EAQQPTQPTSASPSLTATEIIYSEVKKQ
SEQ ID NO:40 (Human Galectin-9)
MAFSGSQAPYLSPAVPFSGTIQGGLQDGLQITVNGTVLSSSGTRFAVNFQTGFSGN
DIAFHFNPRFEDGGYVVCNTRQNGSWGPEERKTHMPFQKGMPFDLCFLVQSSDF
KVMVNGILFVQYFHRVPFHRVDTISVNGSVQLSYISFQPPGVWPANPAPITQTVIH
TVQSAPGQMFSTPAIPPMMYPHPAYPMPFITTILGGLYPSKSILLSGTVLPSAQRFH
INLCSGNHIAFHLNPRFDENAVVRNTQIDNSWGSEERSLPRKMPFVRGQSFSVWIL
CEAHCLKVAVDGQHLFEYYHRLRNLPTINRLEVGGDIQLTHVQT
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission
that such documents, or such sources of information, in any jurisdiction, are prior art, or
form part of the common general knowledge in the art.
Claims (34)
1. An antibody that binds human Tim-3, (SEQ ID NO:1), the antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 wherein: 5 a) HCDR1 has the amino acid sequence of SEQ ID: 2, HCDR2 has the amino acid sequence of SEQ ID NO: 3, HCDR3 has the amino acid sequence of SEQ ID NO: 4, LCDR1 has the amino acid sequence of SEQ ID NO:5, LCDR2 has the amino acid sequence of SEQ ID NO:6, and LCDR3 has the amino acid sequence of SEQ ID NO:7; 10 b) HCDR1 has the amino acid sequence of SEQ ID NO:14, HCDR2 has the amino acid sequence of SEQ ID NO:15, HCDR3 has the amino acid sequence of SEQ ID NO:16, LCDR1 has the amino acid sequence of SEQ ID NO:17, LCDR2 has the amino acid sequence of SEQ ID NO:18, and LCDR3 has the amino acid sequence of SEQ ID NO:19; or 15 c) HCDR1 has the amino acid sequence of SEQ ID NO:26, HCDR2 has the amino acid sequence of SEQ ID NO:27, HCDR3 has the amino acid sequence of SEQ ID NO:28, LCDR1 has the amino acid sequence of SEQ ID NO:29, LCDR2 has the amino acid sequence of SEQ ID NO:30, and LCDR3 has the amino acid sequence of SEQ ID NO:31. 20
2. The antibody of claim 1, wherein HCDR1 has the amino acid sequence of SEQ ID: 2, HCDR2 has the amino acid sequence of SEQ ID NO: 3, HCDR3 has the amino acid sequence of SEQ ID NO: 4, LCDR1 has the amino acid sequence of SEQ ID NO:5, LCDR2 has the amino acid sequence of SEQ ID NO:6, and LCDR3 has the amino acid sequence of SEQ ID NO:7. 25
3. The antibody of claim 1, wherein HCDR1 has the amino acid sequence of SEQ ID NO:14, HCDR2 has the amino acid sequence of SEQ ID NO:15, HCDR3 has the amino acid sequence of SEQ ID NO:16, LCDR1 has the amino acid sequence of SEQ ID NO:17, LCDR2 has the amino acid sequence of SEQ ID NO:18, and LCDR3 has the amino acid sequence of SEQ ID NO:19. 30
4. The antibody of claim 1, wherein HCDR1 has the amino acid sequence of SEQ ID NO:26, HCDR2 has the amino acid sequence of SEQ ID NO:27, HCDR3 has the amino acid sequence of SEQ ID NO:28, LCDR1 has the amino acid sequence of SEQ ID NO:29, LCDR2 has the amino acid sequence of SEQ ID NO:30, and LCDR3 has the amino acid sequence of SEQ ID NO:31.
5. An antibody, comprising a heavy chain variable region (HCVR) and a light chain 5 variable region (LCVR), wherein: a) the HCVR has the amino acid sequence of SEQ ID NO: 8, and the LCVR has the amino acid sequence of SEQ ID NO: 9; b) the HCVR has the amino acid sequence of SEQ ID NO: 20, and the LCVR has the amino acid sequence of SEQ ID NO: 21; or 10 c) the HCVR has the amino acid sequence of SEQ ID NO: 32, and the LCVR has the amino acid sequence of SEQ ID NO: 33.
6. The antibody of claim 5, wherein the HCVR has the amino acid sequence of SEQ ID NO: 8, and the LCVR has the amino acid sequence of SEQ ID NO: 9.
7. The antibody of claim 5, wherein the HCVR has the amino acid sequence of SEQ ID 15 NO: 20, and the LCVR has the amino acid sequence of SEQ ID NO: 21.
8. The antibody of claim 5, wherein the HCVR has the amino acid sequence of SEQ ID NO: 32, and the LCVR has the amino acid sequence of SEQ ID NO: 33.
9. An antibody, comprising a heavy chain (HC) and a light chain (LC), wherein: a. the HC has the amino acid sequence of SEQ ID NO: 10 and the LC has the 20 amino acid sequence of SEQ ID NO: 11; b. the HC has the amino acid sequence of SEQ ID NO: 22 and the LC has the amino acid sequence of SEQ ID NO: 23; or c. the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the amino acid sequence of SEQ ID NO: 35. 25 10. The antibody of claim 9, wherein the HC has the amino acid sequence of SEQ ID NO:
10 and the LC has the amino acid sequence of SEQ ID NO: 11.
11. The antibody of claim 9, wherein the HC has the amino acid sequence of SEQ ID NO: 22 and the LC has the amino acid sequence of SEQ ID NO: 23.
12. The antibody of claim 9, wherein the HC has the amino acid sequence of SEQ ID NO: 30 34 and the LC has the amino acid sequence of SEQ ID NO: 35.
13. The antibody of any one of claims 9-12, wherein the antibody has two of the heavy chains and two of the light chains.
14. The antibody of claim 13, wherein one of the heavy chains forms an inter-chain disulfide bond with one of the light chains, and the other heavy chain forms an inter- 5 chain disulfide bond with the other light chain, and one of the heavy chains forms two inter-chain disulfide bonds with the other heavy chain.
15. The antibody of any one of claims 1-14, wherein the antibody is glycosylated.
16. An isolated mammalian cell expressing an antibody comprising a heavy chain (HC) and a light chain (LC), wherein: 10 a. the HC has the amino acid sequence of SEQ ID NO: 10 and the LC has the amino acid sequence of SEQ ID NO: 11; b. the HC has the amino acid sequence of SEQ ID NO: 22 and the LC has the amino acid sequence of SEQ ID NO: 23; or c. the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the 15 amino acid sequence of SEQ ID NO: 35.
17. The mammalian cell of claim 16, wherein the HC has the amino acid sequence of SEQ ID NO: 10 and the LC has the amino acid sequence of SEQ ID NO: 11.
18. The mammalian cell of claim 16, wherein the HC has the amino acid sequence of SEQ ID NO: 22 and the LC has the amino acid sequence of SEQ ID NO: 23. 20
19. The mammalian cell of claim 16, wherein the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the amino acid sequence of SEQ ID NO: 35.
20. An in vitro process for producing an antibody comprising cultivating a mammalian cell capable of expressing the antibody and recovering the antibody; wherein the antibody comprises a heavy chain (HC) and a light chain (LC),wherein: 25 a. the HC has the amino acid sequence of SEQ ID NO: 10 and the LC has the amino acid sequence of SEQ ID NO: 11; b. the HC has the amino acid sequence of SEQ ID NO: 22 and the LC has the amino acid sequence of SEQ ID NO: 23; or c. the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the amino acid sequence of SEQ ID NO: 35.
21. The process of claim 20, wherein the HC has the amino acid sequence of SEQ ID NO: 10 and the LC has the amino acid sequence of SEQ ID NO: 11. 5 22. The process of claim 20, wherein the HC has the amino acid sequence of SEQ ID NO:
22 and the LC has the amino acid sequence of SEQ ID NO: 23.
23. The process of claim 20, wherein the HC has the amino acid sequence of SEQ ID NO: 34 and the LC has the amino acid sequence of SEQ ID NO: 35.
24. A pharmaceutical composition, comprising the antibody of any one of claims 1-15 10 and an acceptable carrier, diluent, or excipient.
25. Use of an antibody according to any one of claims 1-15 in the manufacture of a medicament for treating cancer.
26. The use of claim 25, wherein the cancer is melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder 15 cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft tissue sarcoma, or liver cancer.
27. The use of claim 26, wherein the lung cancer is non-small cell lung cancer.
28. The use of any one of claims 25-27, wherein the antibody is to be administered in simultaneous, separate, or sequential combination with ionizing radiation. 20
29. The use of any one of claims 25-28, wherein the antibody is to be administered in simultaneous, separate, or sequential combination with one or more chemotherapeutic agents.
30. An antibody according to any one of claims 1 to 15, substantially as herein described with reference to any example thereof. 25
31. An isolated mammalian cell according to any one of claims 16 to 19, substantially as herein described with reference to any example thereof.
32. An in vitro process according to any one of claims 20 to 23, substantially as herein described with reference to any example thereof.
33. A pharmaceutical composition according to claim 24, substantially as herein 30 described with reference to any example thereof.
34. A use according to any one of claims 25 to 29, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379343P | 2016-08-25 | 2016-08-25 | |
| US62/379,343 | 2016-08-25 | ||
| US201762469753P | 2017-03-10 | 2017-03-10 | |
| US62/469,753 | 2017-03-10 | ||
| PCT/US2017/047261 WO2018039020A1 (en) | 2016-08-25 | 2017-08-17 | Anti-tim-3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ749820A NZ749820A (en) | 2021-05-28 |
| NZ749820B2 true NZ749820B2 (en) | 2021-08-31 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10253096B2 (en) | Anti-Tim-3 antibodies | |
| US11352424B2 (en) | Anti-Tim-3 antibodies for combination with anti-PD-1 antibodies | |
| CA3043761C (en) | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies | |
| US10214586B2 (en) | PD-L1 antibodies | |
| US10906983B2 (en) | Anti-CD137 antibodies | |
| US20230279134A1 (en) | Anti-cd137 antibodies | |
| CA3094998A1 (en) | Anti-cd137 antibodies for combination with anti-pd-1 antibodies | |
| US20200157234A1 (en) | Anti-cd137 antibodies | |
| NZ749820B2 (en) | Anti-tim-3 antibodies |